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Summary 
Protein-coding genes in eukaryotes are transcribed by RNA polymerase II (Pol II). This 
process is tightly regulated and coupled to RNA processing. Many transcription and RNA 
processing factors are recruited to Pol II via its conserved C-terminal domain (CTD) 
containing 27 heptapeptide repeats of the consensus sequence Tyr1-Ser2-Pro3-Thr4-Ser5-
Pro6-Ser7 in Saccharomyces cerevisiae. These repeats can be differentially phosphorylated 
during the transcription cycle serving as a code for interacting factors. During transcription 
initiation, Ser5 is phosphorylated at the 5’-end of genes and this phosphorylation is required 
for RNA capping enzyme binding. During transcription elongation, the Pol II CTD becomes 
phosphorylated at Tyr1 and Ser2 and binds the elongation factor Spt5. Spt5 also contains a 
repetitive C-terminal region (CTR) required for cotranscriptional recruitment of proteins. At 
the 3’-end of genes, Ser2-phosphorylated Pol II associates with the cleavage and 
polyadenylation factor (CPF) and is dephosphorylated at Tyr1 residues.  
This work shows that CPF is a Pol II CTD phosphatase and that its subunit Glc7 
dephosphorylates Tyr1 in vitro. In vivo, Glc7 activity is required for normal Tyr1 
dephosphorylation at the polyadenylation (pA) site, for recruitment of termination factors 
Pcf11 and Rtt103, and for normal Pol II termination. These results show that transcription 
termination involves Tyr1 dephosphorylation of the CTD and indicate that pre-mRNA 
processing and transcription termination are coupled via CPF-dependent Pol II Tyr1 
dephosphorylation. Additionally, 19 kinases were tested for activity on Tyr1 in yeast by 
selective inhibition or knock-out in vivo. However, none of the candidates was identified as 
the Tyr1 kinase. Possibly this enzyme is an atypical kinase not known to be involved in 
transcription so far. 
Furthermore, this work reports a new role of the Spt5 CTR in recruitment of RNA 3’-end 
processing factors. The results show that the Spt5 CTR as well as RNA is required for normal 
recruitment of the pre-mRNA cleavage factor (CF) I to the 3’-end of yeast genes. Genome-
wide ChIP profiling detects occupancy peaks of CFI subunits around 100 base pairs 
downstream of the pA site of genes. CFI recruitment to this defined region may result from 
simultaneous binding to the Spt5 CTR, to nascent RNA containing the pA sequence, and to 
the elongating Pol II isoform that is phosphorylated at Ser2 of the CTD. Consistent with this 
model, the CTR interacts with CFI in vitro, but is not required for pA site recognition and 
transcription termination in vivo. 
In summary, we characterized two new aspects of transcription and RNA processing 
regulation by two different C-terminal repetitive protein domains. CTD Tyr1 phosphorylation, 
which is removed by Glc7, regulates termination factor recruitment by masking their binding 
site, the Spt5 CTR is involved in recruitment of CFI. Both results greatly contribute to a more 
detailed understanding of the mechanisms involved in transcription termination and RNA  
3’-end processing. 
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1. Introduction 
1.1. Gene transcription in eukaryotes 
The transfer of information encoded in the DNA sequence into proteins is essential and 
referred to as the central dogma of biochemistry (1). Transcription of genes from a DNA 
template into an RNA sequence is the first step of this pathway and therefore one of the most 
important processes in all living cells. The enzyme that carries out transcription is the DNA-
dependent RNA polymerase (Pol) (2). 
Eukaryotic cells have three nuclear RNA polymerases that perform transcription of DNA:  
Pol I, II and III. Pol I synthesizes ribosomal RNAs (rRNAs) and thereby makes up for 75% of 
transcription in the cell (3-5). Pol II produces protein-coding RNAs as well as small nuclear 
(snRNAs) and small nucleolar RNAs (snoRNAs) (6-8). Pol III is responsible for synthesis of 
transfer RNAs (tRNAs), the 5S rRNA and other small RNA molecules, which accounts for 
another 15% of transcription in cells (5, 9). Although Pol II performs only about 10% of 
transcription in cells, it transcribes about 85% of the whole yeast genome (10, 11).   
All three enzymes are structurally related and consist of a conserved 10-subunit core and 
specific additional subunits (12). Pol II, however, is the only polymerase containing a flexible 
C-terminal repeat domain (CTD) on its largest subunit Rpb1 (13). It is commonly accepted 
that the CTD is necessary for Pol II regulation (14, 15). 
Additional polymerases in eukaryotic cells are the mitochondrial polymerase, a single-subunit 
polymerase similar to the bacteriophage T7 polymerase (16), which transcribes the 
mitochondrial genome, and Pol IV and V in plant cells which regulate non-coding RNA 
mediated gene silencing (17). 
RNA polymerase II transcribes through a chromatin environment in which the DNA is 
wrapped around nucleosomes like “beads on a string” (18, 19). Each nucleosome is wrapped 
in 147 bp of DNA (20) and consists of eight subunits: two histone H2A/H2B dimers and one 
histone H3/H4 tetramer (21). This packaging structure of DNA and proteins can prevent 
access of Pol II to the DNA and thus can inhibit transcription (19). As a consequence, 
chromatin remodelers with the help of sequence-specific regulators have to rearrange 
chromatin to control specific expression of genes (22).  
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1.2. The RNA polymerase II CTD 
1.2.1. CTD sequence and structure 
The CTD of Pol II, which is conserved from yeast to human, forms a flexible extension of the  
Pol II subunit Rpb1 consisting of multiple heptapeptide repeats of the consensus sequence 
Tyr1-Ser2-Pro3-Thr4-Ser5-Pro6-Ser7 (Y1S2P3T4S5P6S7) (23). The number of repeats 
increases with the complexity of the organism ranging from 27 repeats in Saccharomyces 
cerevisiae (S. cerevisiae), S288C strain (24), to 42 repeats in Drosophila melanogaster  
(D. melanogaster) and 52 in Homo sapiens (H. sapiens) (23, 25) (Figure 1).  
According to Figure 1, not only the CTD length but also the number of consensus repeats 
varies considerably between organisms. Whereas the yeast CTD contains 19 out of 27 
consensus repeats (70%), the human CTD contains only 21 out of 52 (40%) and the  
D. melanogaster CTD only 2 out of 42 (5%). All consensus repeats of the human CTD are 
located in the proximal part of the CTD, closer to the body of Pol II and the linker. The distal 
part of the CTD consists exclusively of non-consensus repeats. A study in mice showed that 
the deletion of several non-consensus repeats of the CTD leads to defects in growth and 
development (26), whereas in yeast, a CTD with only consensus repeats does not show any 
defects (27). Therefore, it is possible that the longer CTD was acquired during evolution to 
take over more diverse functions. A polymerase is able to transcribe without a CTD in vitro 
(28), but the repeats are absolutely necessary for cell viability (24, 25, 29, 30). Yeast tolerates 
a truncation of the CTD down to eight repeats, but these cells grow slowly and show 
temperature sensitivity (27). In mice, a truncation to 29 of 52 repeats is possible (29). 
However, this truncation was done only in cell culture and the situation might be different in 
living organisms (31). 
The CTD is thought to be mainly unstructured and flexible as it was not detected in the Pol II 
crystal structure (32), but it is able to form β-turns (33). CTD phosphorylation in turn leads to 
unfolding of secondary structure and extension of the repeat sequence (34). 
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Figure 1: Pol II CTD sequences in S. cerevisiae, D. melanogaster and H. sapiens.  
Consensus repeats are highlighted in yellow, all residues diverging from the consensus sequence are shown in 
red (25, 31).  
 
1. Introduction 
4 
 
As mentioned above, the consensus repeat Y1S2P3T4S5P6S7 is conserved from yeast to human. 
Mutation of Ser2 or Ser5 of the CTD repeats in S. cerevisiae to alanine (Ala) or glutamate 
(Glu) as a phosphomimetic results in an inviable phenotype (27). An exchange of all Tyr1 
residues to phenylalanine (Phe) is also lethal (27). In contrast to that, mutations of Thr4 or 
Ser7 to Ala are viable in yeast (35), whereas mutation of Ser7 to Glu is lethal (36). Thus, the 
amino acids of the consensus repeat are of different importance for CTD function with Tyr1, 
Ser2 and Ser5 being crucial for viability. Interestingly, the mutations of Tyr1 to Phe or Ser2 to 
Ala are not lethal in Schizosaccharomyces pombe (S. pombe) (37) but Thr4 to Ala is lethal in 
human cells (38). Taken together, these reports indicate that the CTD residues – although the 
sequence is conserved – may have diverging functions in other organisms.  
Mutational studies by Stiller and Cook additionally showed that introducing Ala residues 
between every heptapeptide repeat is lethal in yeast, whereas an Ala residue after every 
second repeat is viable (39). Thus, the CTD repeats are functioning in pairs. By mutating the 
last residues of every diheptad to Ala, it was found in S. pombe that only a decapeptide 
YSPTSPSYSP is necessary for viability (40) and in S. cerevisiae, a mutant with 
YSPTSPSYSPTAAA repeats was still viable (41). The underlined sequence is termed the 
minimal functional unit of the CTD (41). 
1.2.2. Posttranslational modifications of the CTD 
The CTD can be reversibly posttranslationally modified as is schematically shown in  
Figure 2 for one repeat (42-46). These modifications are thought to serve as a CTD code that 
is recognized by interacting proteins, the “CTD readers”, which are specifically recruited to a 
distinctly modified CTD (47, 48).  
 
Figure 2: Model of the yeast Pol II CTD repeats and possible posttranslational modifications of a 
consensus repeat.  
The 27 CTD repeats are depicted as boxes, green indicates consensus repeats. The consensus sequence with its 
possible modifications is shown below the repeats. G: Glycosylation (only shown in mammals, (45, 49)); P: 
phosphorylation (same color code is used during this work, (43, 44)); double arrow: cis/trans isomerization (46). 
Five out of seven residues within one yeast CTD repeat can be phosphorylated, of which Ser2 
and Ser5 are the most studied phosphorylation sites (38, 44, 50, 51). The CTD phosphoryla-
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tions have been mapped along transcribed genes: Ser5 and Ser7 phosphorylation levels peak 
shortly after the transcription start site (TSS), with Ser7-P peaking slightly before Ser5-P (43). 
Tyr1 and Ser2 phosphorylations gradually increase along the transcribed region and reach 
peak levels around the polyadenylation (pA) site (44) (chapter 1.4). Thr4 phosphorylation has 
not been extensively studied in yeast.  
The various CTD phosphorylations play an important role in the Pol II transcription cycle 
(chapter 1.3, (42)). Therefore, the kinases and phosphatases, termed “writers and erasers” of 
the CTD code (47), have been of great interest and are summarized in Table 1.  
Table 1: Known in vivo CTD kinases and phosphatases in S. cerevisiae (adapted from (47)). 
Specific CTD phosphorylation Kinase Phosphatase 
Tyr1 -- -- 
Ser2 Bur1, Ctk1  Fcp1 
Thr4 -- -- 
Ser5 Kin28, Srb10, Cdc28 Ssu72, (Rtr1) 
Ser7 Kin28 Ssu72 
Kin28, which is part of transcription factor TFIIH, introduces the first phosphorylations on 
Ser5 and Ser7 during the transcription cycle (50, 52). Other kinases were also proposed to 
phosphorylate Ser5 such as Srb10, a subunit of the Mediator, and Cdc28 (53-55). The main 
phosphatase for Ser5-P and Ser7-P, which signals decrease after transcription initiation, is 
Ssu72 (36, 56). However, as Ssu72 is a component of the cleavage and polyadenylation factor 
(CPF), it is recruited mainly at the 3’-end of genes and thus possibly not the enzyme that 
decreases Ser5-P levels directly after initiation. Another protein that was proposed to 
dephosphorylate Ser5-P in the 5’ region of genes is the atypical phosphatase Rtr1 (57), 
although the mechanism of its recruitment remains unclear. Furthermore, it was shown 
recently that Rtr1 does not contain an active site and that it most likely only plays a regulatory 
role in Ser5-P dephosphorylation (58). Ser2 is phosphorylated during elongation by two 
kinases: Ctk1 and Bur1. Although Ctk1 is thought to be the major Ser2 kinase in vivo (59-61), 
its deletion does not completely abolish Ser2 phosphorylation. A second kinase, Bur1, 
additionally contributes to Ser2 phosphorylation (60). The main Ser2-P phosphatase is Fcp1 
(59), which shows highest occupancy levels at the 3’-ends of genes in accordance with the 
decrease of Ser2-P levels (36). Interestingly, neither kinases nor phosphatases for Tyr1 or 
Thr4 residues have yet been identified in yeast. In mammals, Thr4 is phosphorylated by Plk3 
(38) and Tyr1 by c-Abl (62). As Tyr1 is an essential residue of the CTD in yeast, it is of great 
interest to identify the enzymes which modulate phosphorylation of Tyr1. This issue is 
extensively addressed as part of this work (chapters 2 and 3).  
1. Introduction 
6 
 
Another posttranslational modification of the CTD, which has so far only been shown in 
mammals, is O-GlcNAcylation (49), the addition of O-linked N-acetylglucosamine  
(O-GlcNAc) to serine or threonine residues. This modification can be added to Thr4, Ser5 or 
Ser7 residues and is mutually exclusive with CTD phosphorylation (45). As the O-GlcNAc 
transferase has been shown to be a part of the preinitiation complex (PIC) in higher 
eukaryotes, it is proposed, that CTD glycosylation can regulate transcription initiation (45).  
The proline residues of the CTD repeats can also be modified by cis-trans-isomerization (46). 
In S. cerevisiae, the essential isomerase Ess1 is responsible. The trans configuration is 
generally more stable, but it has been shown that the Ser5 phosphatase Ssu72 only binds the 
Ser5-phosphorylated CTD when the Ser5-Pro6 bond is in cis configuration (63). In contrast to 
that, the termination factor Pcf11 binds to Ser2-P when the Ser2-Pro3 bond is in trans 
configuration (64, 65). Mammalian non-consensus repeats have also been shown to be 
methylated on arginine at position 7 in repeat 31 (Arg1810) by coactivator-associated arginine 
methyltransferase 1 (CARM1) (66) and six lysines in the mouse CTD can be ubiquitinated by 
a ubiquitin ligase (67). 
If all theoretically possible posttranslational modifications of one yeast CTD repeat are taken 
into account (phosphorylation and proline isomerization), 2 states for each residue would be 
possible, which results in 27 = 128 combinations per repeat. For the complete yeast CTD, this 
would be 2173 = 1.2 × 1052 possibilities. In mammals, with glycosylation and methylation and 
more repeats, this number would be even higher. This complexity raises the question why the 
CTD has evolved as it is now and if all of these possible states are present in living cells.  
So far it is known that specific CTD marks serve as a code for recruitment of a myriad of 
interacting proteins, the CTD code readers (47). Table 2 gives an overview of important 
readers in yeast.  
Table 2: Important Pol II CTD readers in S. cerevisiae (adapted from (42)). 
Protein (complex) Function CTD phosphorylation state 
TFIIE transcription initiation unphosphorylated CTD 
TFIIF transcription initiation unphosphorylated CTD 
TBP transcription initiation unphosphorylated CTD 
Mediator transcription initiation unphosphorylated CTD 
Ceg1 (capping enzyme) guanylyltransferase, RNA 5’ capping Ser5-P 
Abd1 methyltransferase, RNA 5’ capping in vitro phosphorylated CTD 
Set1 (COMPASS) histone methylation (H3K4me3) Ser5-P 
Spt6 nucleosome remodeling Ser2-P 
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Protein (complex) Function CTD phosphorylation state 
Nrd1 termination of non-polyadenylated 
transcripts 
Ser5-P 
Ess1 proline isomerization in vitro phosphorylated CTD 
Set2 histone methylation (H3K36me3) Ser2-P/Ser5-P 
Prp40 RNA splicing in vitro phosphorylated CTD 
Pcf11 (CFIA) mRNA cleavage and polyadenylation Ser2-P 
Rna14 (CFIA) mRNA cleavage and polyadenylation in vitro phosphorylated CTD 
Rna15 (CFIA) mRNA cleavage and polyadenylation in vitro phosphorylated CTD 
Ydh1 (CPF) mRNA cleavage and polyadenylation in vitro phosphorylated CTD 
Yhh1 (CPF) mRNA cleavage and polyadenylation in vitro phosphorylated CTD 
Pta1 (CPF) mRNA cleavage and polyadenylation Ser5-P 
Rtt103 interaction with exonucleases, 
transcription termination 
Ser2-P 
Yra1 mRNA export Ser2-P/Ser5-P 
The following chapter 1.3 includes all CTD readers mentioned above into a picture of the  
Pol II transcription cycle including RNA processing and important changes in the chromatin 
environment. 
1.3. The Pol II transcription cycle 
In the course of the Pol II transcription cycle, changes in CTD phosphorylation coordinate 
recruitment of transcription and RNA processing factors to the polymerase (14, 15, 68). Pol II 
CTD phosphorylation profiles along the transcribed region of yeast genes are shown in  
Figure 6 and (43). How these phosphorylations determine factor recruitment will be covered 
in the following chapter. Figure 3 depicts a simplified model of the Pol II transcription cycle 
and important CTD phosphorylations.  
1.3.1. Transcription initiation 
In the first step of the transcription cycle (Figure 3, Initiation), RNA Pol II with an 
hypophosphorylated CTD associates with general transcription factors (GTFs) and the 
mediator complex at the promoter DNA to form the PIC (15), whereby the GTFs TBP, TFIIE 
and TFIIF as well as the Mediator complex directly interact with the CTD (69-72). Lastly, 
TFIIH is recruited to the PIC (69) and its kinase subunit Kin28 phosphorylates the CTD on 
Ser5 and Ser7 residues (52, 53). Ser5 phosphorylation leads to dissociation of Mediator and to 
promoter clearance (73). 
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Figure 3: Schematic overview of the Pol II transcription cycle in S. cerevisiae.  
DNA is depicted as a blue line with histones in yellow and RNA as a red line. Pol II and its CTD are in black. 
CTD phosphorylations Ser2-P, Ser5-P, Ser7-P are depicted as blue, red and light blue dots, respectively. (GTFs: 
general transcription factors; CE: capping enzyme; CF: cleavage factor; CPF: cleavage and polyadenylation 
factor). For details see within text. 
1.3.2. Transcription elongation 
After transcription initiation, the Ser5-phosphorylated CTD (Ser5-P) together with the  
C-terminal repeats of transcription elongation factor Spt5 (chapter 1.3.3) recruits the RNA  
5’-capping machinery (50, 74, 75), which adds the 5’ guanine-N7 methyl cap (m7G) to 
nascent RNAs to prevent them from degradation (76) and to enhance mRNA translation 
initiation (77). The capping reaction comprises three steps: In S. cerevisiae at first the RNA  
5’ triphosphatase Cet1 removes the γ-phosphate from the 5’ triphosphate, then the 
guanylyltransferase Ceg1 adds an inverted guanylyl group by 5’-5’ triphosphate linkage, and 
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finally the methyltransferase Abd1 adds a methyl group to the N7 atom of the terminal 
guanine group (78). Ceg1 and Abd1 thereby have been shown to interact directly with the  
Pol II CTD (74, 79). Ser5-P also recruits the early termination factor Nrd1 (80) and the 
histone methyltransferase Set1, which trimethylates histone 3 on lysine 4 (H3K4me3) (81), a 
chromatin mark for transcriptional activity. A function for the high level of Ser7 
phosphorylation (Ser7-P) at the 5’-ends of genes has so far only been shown for mammals, 
where Ser7-P recruits the Integrator complex, which is involved in snRNA 3’-processing (82). 
A function of Ser7-P in yeast still has to be determined. However, as it is lethal in yeast to 
mutate Ser7 to Glu (chapter 1.2.1), this residue most likely has to be unphosphorylated at 
some stage and therefore, a negative function of Ser7-P is possible. 
During transcription elongation, Ser5-P is gradually dephosphorylated either by Rtr1 or Ssu72 
(57), whereas Ser2 is phosphorylated (Ser2-P) by the joint action of Bur1 and Ctk1 (43). In 
the course of this process, transcription elongation factors are recruited to Pol II to enable 
productive elongation. Spt4 and Spt5 are needed to ensure Pol II transcription processivity 
(chapter 1.3.3, (83, 84)). The Paf1 complex, the histone chaperone Spt6, and the FACT 
complex are important for ensuring proper transcription through chromatin: The Paf1 
complex consists of the five proteins Paf1, Ctr9, Cdc73, Rtf1, and Leo1 in yeast and is 
involved in recruitment of histone methyltransferase Set1 (85). It is recruited via the 
phosphorylated C-terminal repeats of Spt5 (86, 87) (chapter 1.3.3). Spt6 directly interacts 
with Pol II via the CTD phosphorylated on Ser2 (88) and together with the FACT complex it 
is involved in nucleosome remodeling to enable transcription through chromatin and to 
prevent transcription from cryptic promoters (89, 90). 
The Ser2-P/Ser5-P double phosphorylation mark of the CTD recruits the histone 
methyltransferase Set2, which trimethylates histone 3 on lysine 36 (H3K36me3) (91). The 
histone marks H3K4me3 and H3K36me3 marks add another level of transcriptional 
regulation to the CTD code, the “histone code” (92). Additionally, the general mRNA export 
factor Yra1 is recruited by the bivalent Ser2-P/Ser5-P mark on the yeast CTD (93). It binds 
the CTD as well as RNA and targets the mRNAs for nuclear export (94). Proline isomerase 
Ess1 and splicing factor Prp40 have been shown to interact with an in vitro 
hyperphosphorylated CTD (95, 96). The direct interaction between a splicing factor and the 
CTD suggests that the CTD can also regulate splicing. Pre-mRNA splicing removes non-
coding parts of a gene (introns) and joins the two flanking DNA sequences (exons) (97). In  
S. cerevisiae, only 5% of the genes contain introns (98). The spliceosome complex, consisting 
of five small nuclear ribonucleic particles (snRNPs) and numerous other proteins, catalyzes 
the splicing reaction, which is performed in two transesterification reactions (97, 99). 
With increasing Ser2-P levels during transcription elongation, RNA cleavage and polyadeny-
lation factors are recruited (chapter 1.3.4).  
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1.3.3. The elongation factor Spt5 
In contrast to many transcription factors that are recruited via the Pol II CTD, some 
elongation factors, including TFIIS (100) and Spt5 (84, 101), also bind the body of Pol II. The 
gene encoding Spt5 was identified in S. cerevisiae as a suppressor of transposon insertion in 
the promoter region of the HIS4 gene (102). Spt5 is an essential nuclear protein (103) and 
binds Spt4 (83). Spt5 associates with Pol II in vivo, and mutations lead to a slow-growth 
phenotype in the presence of the nucleotide-depleting drug 6-azauracil (6-AU), arguing for a 
role of Spt5 in transcription elongation (83). The human homolog of yeast Spt4/5 affects  
Pol II elongation (104). Chromatin immunoprecipitation (ChIP) revealed that Spt5 colocalizes 
with Pol II throughout the transcribed region and past the pA site (43, 105-107). Spt4/5 is 
present on all transcribed yeast genes and is a general component of the elongation complex 
(43, 107). Spt4/5 also associates with Pol I (108) and Pol I genes (109). Spt5 is the only 
known Pol II-associated factor that is conserved in all three kingdoms of life (110). The 
bacterial Spt5 homolog NusG and archaeal Spt5 consist of a NusG N-terminal homology 
(NGN) domain and a flexibly linked C-terminal Kyrpides-Ouzounis-Woese (KOW) domain 
(111, 112). The structures of archaeal Spt4/5 bound to RNA polymerase or its clamp domain 
are known (84, 101). These structures indicate that the NGN domain closes the active center 
cleft to lock nucleic acids and render the elongation complex stable and processive (84, 101, 
113). Eukaryotic Spt5 possesses additional regions and domains. Yeast Spt5 consists of an 
acidic N-terminal region, followed by an NGN domain, five KOW domains, and a repetitive 
C-terminal region (CTR) (86, 103, 114) (Figure 4).  
 
Figure 4: Schematic overview of Spt5 domain architecture (84, 86). 
Numbers indicate positions in the amino acid sequence, the repetitive C-terminal region (CTR) is highlighted in 
red, single hexapeptide repeat sequences within the CTR are depicted below the scheme in grey. Acidic: 
Asp/Glu-rich region; NGN: NGN domain; KOW: 5 KOW domains. 
Spt5 has recently emerged as a platform that recruits factors to elongating Pol II. Spt5 
copurifies with over 90 yeast proteins that are involved in transcription elongation, RNA 
processing, transcription termination, and mRNA export (115). Spt4/5 interacts with the 
histone chaperone Spt6 to modulate chromatin structure (83, 116). Spt5 colocalizes with Spt6 
and Pol II at transcriptionally active loci on D. melanogaster polytene chromosomes (117, 
118). Spt5 interacts with and recruits the capping enzyme (119, 120) as well as the Paf1 
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complex (86, 87). Mammalian Spt5 recruits the activation-induced cytidine deaminase to 
DNA during antibody gene diversification (121). Yeast Spt4/5 recruits She2 to nascent RNA, 
coupling mRNA localization with Pol II transcription (122). Recruitment of factors can be 
mediated by the CTR of Spt5 (86, 123, 124). The yeast CTR recruits the Paf1 complex as well 
as the capping enzyme (75, 86, 87), and the fission yeast CTR binds the capping enzyme 
(119). Recently, the CTR was implicated to be involved in recruiting the histone deacetylase 
subunit Rco1 (125). The CTR forms a repeat structure similar to the Pol II CTD (103). The  
S. cerevisiae CTR consists of 15 hexapeptide repeats of the consensus sequence 
S[T/A]WGG[A/Q] (positions where alternative amino acids can occur between different 
repeats are indicated by brackets, and varying amino acids are indicated by slashes), whereas 
the human CTR consists of pentapeptide repeats with the consensus sequence GS[R/Q]TP 
(124) and the fission yeast CTR consists of nonapeptide repeats with the consensus sequence 
TPAWNSGSK (119). Deletion of the Spt5 CTR in yeast is not lethal (86, 87, 126) but leads 
to sensitivity to 6-AU and a slow-growth phenotype at 16°C (86, 87). The CTR deletion is 
synthetically lethal with the deletion of the gene coding for the Pol II CTD kinase Ctk1 (87). 
Deletion of the CTR in fission yeast leads to a slow-growth phenotype and abnormal cell 
morphology (123). The slow-growth phenotype is intensified if the Pol II CTD is truncated 
(123), suggesting that the CTR cooperates with the CTD. Deletion of the CTR impairs 
embryogenesis in zebrafish and leads to a derepression of gene transcription in zebrafish and 
human cells (127). Similar to the Pol II CTD, the CTR of Spt5 can be phosphorylated by the 
kinases Bur1 and P-TEFb in yeast and humans, respectively (86, 87, 124). CTR 
phosphorylation promotes transcription elongation in yeast and is important for the 
cotranscriptional recruitment of the Paf1 complex and for histone modification (86, 87). In 
human cells, CTR phosphorylation by P-TEFb converts Spt5 from a negative to a positive 
elongation factor (124). The Spt5 CTR may also play a role in the suppression of 
transcription-coupled nucleotide excision repair in yeast (126) and is involved in RNA 3’-end 
processing (chapter 4).  
1.3.4. Transcription termination and RNA 3’-end processing 
Protein-coding genes are transcribed until about 200 bp past the pA site in yeast, where Pol II 
is then dissociated from the DNA (128). Two models have been proposed for the termination 
process (129): In the “anti-terminator model”, Pol II dissociates from the DNA at a certain 
point when the pA site signal triggers the release of an anti-terminator factor within the 
transcription machinery (130, 131). In the “torpedo model”, the mRNA is cleaved at the pA 
site and as Pol II transcribes further downstream, a new uncapped 5’-end of this downstream 
product is exposed. This RNA is then degraded by the 5’-3’ exonuclease Rat1/Rai1, which 
triggers Pol II termination (132, 133). The exonuclease complex also contains Rtt103, which 
directly interacts with Pol II phosphorylated on Ser2 of the CTD. This interaction enables 
tight coupling between transcription and termination (132, 134). The most important 
difference between the two models is that in the “torpedo” model, RNA cleavage is an 
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absolute prerequisite for termination, whereas it is not needed in the “anti-terminator model” 
(131). Most likely, termination takes place as a mixture of both models (135). 
After Pol II has transcribed past the pA site, the nascent mRNA is processed in two steps: 
endonucleolytic cleavage and addition of a polyA tail (136). These processes depend on two 
multi-subunit complexes in yeast: cleavage factor I (CFI) and CPF (137). CFI can be 
separated into CFIA and CFIB (138, 139). CFIA consists of Clp1, Rna14, Rna15, and Pcf11 
(140-142), CFIB consists of Hrp1 (138, 143, 144). Whereas all CFIA subunits have homologs 
in mammalian cells, no homologs of CFIB are currently known in higher eukaryotes (137). 
Both complexes can be recruited to the transcription machinery via the phosphorylated Pol II 
CTD (42). This recruitment mechanism is very important in addition to RNA binding of the 
3’-end processing factors as deletion of the CTD leads to defects in RNA cleavage (145). This 
again indicates a tight coupling between the CTD and mRNA processing. The CFI subunit 
Pcf11 interacts with Ser2-phosphorylated CTD via its CTD-interacting (CID) domain (65). 
Ser2 phosphorylation peaks around the pA site and therefore serves as a termination signal 
(43, 146). Pcf11 bridges between Pol II and the RNA and by these two interactions it can 
dismantle elongation complexes in vitro (147). Two other subunits, Rna14 and Rna15 have 
also been shown to bind phosphorylated CTD in vitro (148). CPF subunits Ydh1, Yhh1 and 
Pta1 interact with the phosphorylated CTD (149-151). The necessary RNA signal sequences 
consist of an adenine-rich efficiency element, an adenine-rich positioning element about 30 bp 
upstream of the cleavage site and a uridine-rich element around cleavage and pA site (128). 
CPF and CFI bind to these RNA signals when Pol II transcribes over the pA site. The RNA is 
cleaved and polyadenylated by polyA polymerase Pap1 (141) and polyA binding proteins 
(PAB) then protect the 3’-end from degradation (152). When the mRNA is polyadenylated, it 
can be exported from the nucleus to enter translation. The Pol II CTD is dephosphorylated by 
Ssu72, a member of the CPF complex present at the 3’-ends of genes (153) (chapter 3) and 
Fcp1, which dephosphorylates Ser2-P (154, 155). The hypophosphorylated polymerase can 
then enter a new round of transcription (156). 
The following chapter describes the discovery and first characterization of another important 
CTD modification in yeast, Tyr1-P, which was also found to play a role in transcription 
termination (44). 
1.4. CTD Tyr1 phosphorylation impairs termination factor recruitment to Pol II 
In the following chapter, parts of the recently published paper with the above title are 
presented (44). Author contributions are listed on page IV.  
It was observed by Mayer et al. that the profiles of CTD Ser2 phosphorylation and Pcf11 
occupancy do not correlate well (43). Pcf11 is recruited later than an interaction with Ser2-P 
might suggest. Therefore, the question was raised, whether Ser2-P could be masked along the 
coding region of genes and only become accessible for Pcf11 at the pA site (43). A possible 
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candidate for masking Ser2-P could be Tyr1 phosphorylation of the CTD (44). Although CTD 
phosphorylation on Tyr1 has long been known for human Pol II (62), it has never been shown 
in yeast. Since now specific antibodies against single phosphoresidues of the CTD are 
available, e.g. against Ser2-P (3E10) and Ser5-P (3E128) (generated by Dirk Eick and 
Elisabeth Kremmer, Helmholtz-Zentrum München), these modifications can be detected well. 
In this study, a similar monoclonal antibody for Tyr1-P (3D12) was generated (44).  
1.4.1. A monoclonal antibody against Tyr1-phosphorylated CTD 
Since the functional CTD unit is a pair of repeats (39), we determined antibody specificity 
using diheptapeptides bearing combinations of phosphorylations (Figure 5a, (44)). This 
revealed a high affinity for the Tyr1-phosphorylated CTD that was not impaired by adjacent 
Ser2-P, and no affinity to other CTD peptides (Figure 5a, (44)). The antibody 
immunoprecipitated Pol II from extracts of the yeast S. cerevisiae (Figure 5b), and the 
precipitated polymerases were also phosphorylated at Ser2, Ser5 and Ser7 (44). The antibody 
also recognized Pol II that was purified from human cells with antibody 1C7 (44) and 
phosphorylated in vitro by the Tyr1 kinase c-Abl (157) (Figure 5c). Thus, antibody 3D12 
specifically recognizes the Tyr1-phosphorylated CTD, and Tyr1 phosphorylation occurs in 
yeast. 
 
Figure 5: Pol II CTD is phosphorylated at Tyr1 (44). 
(a) Part of the CTD sequence around phosphorylated Tyr1 (Y1). Residues Ser2, Pro3, Thr4, Ser5, Pro6, and Ser7 
are denoted S2, P3, T4, S5, P6, and S7, respectively. CTD residues that interfere with 3D12 antibody binding 
upon phosphorylation are highlighted in black. (b) Western blot analysis of whole-cell extract from proliferating 
yeast (Input). Pol II was immunoprecipitated with antibodies 8WG16, 3D12, and 1C7 (IP Pol II) and probed 
with 8WG16 or 3D12. Isotype controls are shown. Ig, immunoglobulin. (c) Antibody 3D12 detects CTD Tyr1 
phosphorylation in HeLa cells (Input). Unphosphorylated Pol II was immunoprecipitated with antibody 1C7 (IP 
1C7, (38)) and incubated with c-Abl kinase, leading to a 3D12 signal (IP + c-Abl). The hyper- (II0) and 
hypophosphorylated forms (IIA) of Pol II are indicated. 
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1.4.2. Tyr1 is phosphorylated in the coding region of genes 
To investigate whether genome-associated Pol II is phosphorylated at Tyr1, we used high-
resolution ChIP profiling in proliferating yeast (43). Data from two biological replicates 
(Pearson correlation coefficient R = 0.94, (44)) were averaged and revealed strong signals 
over protein-coding and small nucleolar RNA genes. Gene-averaging of ChIP profiles (43) 
revealed Tyr1 phosphorylation in the coding region (Figure 6a, b). Whereas Tyr1-P signals 
were low at promoters, they increased downstream of the TSS. The gene-averaged profile 
resembled that for Ser2 phosphorylation, except that Ser2-P signals persist downstream of the 
pA site for ~200 bp, whereas Tyr1-P signals decrease already ~180 bp upstream of the pA site 
(Figure 6a, b). The point of Tyr1-P signal increase was dependent on the TSS, whereas the 
point of decrease was dependent on the pA site, but not on gene length or expression level 
(44). These results indicate that Tyr1-P marks are set and removed within the transcription 
cycle. 
 
Figure 6: Gene-averaged ChIP profiles for CTD phosphorylations and termination factors (44). 
(a) DNA frame with promoter, 5′-untranslated region (UTR), open reading frame (ORF), and 3′-UTR. Dashed 
black lines indicate the TSS and pA sites. The dashed gray line marks the position 180 bp upstream of the pA 
site. (b) Gene-averaged profiles for Ser5 (43), Ser2 (43), and Tyr1 phosphorylation for 339 genes of medium 
length (1238 ± 300 bp). (c) Gene-averaged profiles for Nrd1, Pcf11 (43) and Rtt103. ChIP-chip occupancy of 
Nrd1 and Rtt103 is on the left y-axis, Pcf11 occupancy on the right y-axis. 
1.4.3. Tyr1-P negatively influences termination factor recruitment 
To investigate whether Tyr1 phosphorylation influences factor recruitment to Pol II, we 
determined genomic occupancy profiles for termination factors Nrd1, Rtt103, and Pcf11, 
which contain a CTD-interacting domain. The gene-averaged Nrd1 occupancy peaked at the 
beginning of the transcribed region, 193±44 bp downstream of the TSS (Figure 6c). This 
region also showed maximum signals in Ser5-P, and genomic Nrd1 and Ser5-P profiles 
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correlate (R = 0.6), consistent with Nrd1 binding to the Ser5-phosphorylated CTD (80). The 
general presence of Nrd1 at protein-coding genes extends previous results (158, 159) and 
befits a role of Nrd1 in early transcription termination (15, 160-162). Rtt103 showed peak 
occupancy at the end of genes, 112±27 bp downstream of the pA site, where peak levels of 
Pcf11 were also observed (43) (Figure 6c, (44)). Since this region shows the maximum 
difference between Ser2 and Tyr1 phosphorylation signals, Tyr1-P may impair recruitment of 
Rtt103 and Pcf11 upstream of the pA site. Consistent with this, genome-wide occupancies of 
Rtt103 and Pcf11 do not correlate well with Ser2-P signals (R = 0.4, for both), although both 
proteins bind the Ser2-phosphorylated CTD (65, 163).  
To test whether Tyr1 phosphorylation impairs CTD binding of termination factors, we 
determined the affinity of purified recombinant CIDs of yeast Nrd1, Pcf11, and Rtt103 for 
various CTD diheptad phosphopeptides using fluorescence anisotropy (44). None of the CIDs 
bound to an unphosphorylated CTD peptide. Consistent with previous results (80, 163), 
Pcf11-CID and Rtt103-CID bound to the Ser2-phosphorylated CTD peptide (Dissociation 
constant KD=54±6 µM and 12±2 µM, respectively; (44)), whereas the Nrd1-CID 
preferentially bound to a Ser5-phosphorylated CTD peptide (KD = 85±25 µM). In contrast, 
none of the CIDs bound Tyr1-phosphorylated CTD peptides, regardless of whether additional 
phosphorylations were present or not. Thus, Tyr1 phosphorylation blocks CID binding to the 
CTD in vitro, consistent with the hypothesis that it impairs termination factor recruitment in 
vivo. 
1.4.4. The extended CTD code 
Our results extend the previously proposed CTD code (68, 164, 165), which was based on 
Ser2 and Ser5 phosphorylation, leading to an extended CTD code for the coordination of the 
transcription cycle with factor recruitment (Figure 7).  
During initiation and early elongation, the CTD is phosphorylated on Ser5, which facilitates 
recruitment of the capping enzyme and Nrd1. 150-200 bp downstream of the TSS, peak 
occupancy levels are reached for Nrd1 and Pol II (43), likely marking a decision point where 
Pol II transiently pauses and either terminates or continues elongation (15). When Tyr1-P and 
Ser2-P levels rise, Pol II binds elongation factors stably and continues elongation. Tyr1-P 
releases Nrd1 and impairs recruitment of Rtt103 and Pcf11, suppressing termination during 
elongation. Before the pA site, Tyr1-P levels drop, whereas Ser2-P levels remain high. This 
enables recruitment of Rtt103 and Pcf11 that is enhanced by cooperative interactions between 
factors (163) and with nascent RNA (159), resulting in RNA 3’-end processing and 
transcription termination. Our results indicate that Tyr1 CTD phosphorylation is a target to 
activate transcription by suppressing Pol II termination, and explain why mutation of Tyr1 to 
phenylalanine, which lacks the oxygen atom required for phosphorylation, is lethal (27). 
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Figure 7: Extended CTD code for transcription cycle coordination (44). 
During the cycle, levels of CTD phosphorylation at Tyr1, Ser2, and Ser5 residues change differently, as 
illustrated by gradients of red (Ser5-P), blue (Ser2-P) and violet (Tyr1-P) in three semicircles. 
1.5. Aims and scope of this work 
Gene transcription in eukaryotes is a highly regulated process (chapter 1.3). It has been 
known for a long time that the Pol II CTD plays a central role in regulating transcription (68). 
The CTD coordinates transcription with RNA processing steps in a chromatin environment. 
During the transcription cycle different posttranslational phosphorylations on the CTD 
facilitate the recruitment of many different factors by generating a CTD code (164). 
Phosphorylations on Ser5 and Ser2 residues are already established as main regulators of 
transcription and RNA processing: Ser5 phosphorylation is important for capping enzyme 
recruitment (50, 74), which in turn promotes the transition from transcription initiation to 
elongation (75). In contrast to that, Ser2 phosphorylation is involved in transcription 
termination as it recruits Pcf11 (65). 
We found recently that the existing CTD code can be extended by an additional 
phosphorylation, Tyr1-P (chapter 1.4.4, (44)). Its genome-wide profile peaks towards the  
3’ region of genes before the pA site (Figure 6). A possible role of Tyr1-P in regulating 
termination was therefore assumed.  
As we found the first evidence of Tyr1 phosphorylation in yeast, this modification, its kinase 
or phosphatase and its function have been completely uncharacterized until now. Three 
questions immediately arose, that were addressed in this work: (i) which kinase 
phosphorylates Tyr1 in yeast (chapter 2); (ii) which phosphatase dephosphorylates Tyr1-P 
(chapter 3); (iii) what function does Tyr1-P have in transcription termination (chapter 3). 
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To address these questions we mainly used ChIP, a method that measures the binding of 
proteins to specific DNA sequences (chapter 6.2.6, (166)). In short, by addition of 
formaldehyde DNA, proteins and RNA in close proximity are crosslinked, the DNA is then 
fragmented and the protein/modification of interest immunoprecipitated. DNA sequences that 
are bound to this protein/modification are enriched in the immunoprecipitated sample and 
after reversal of crosslinks can be quantified. Transcribing Pol II modifications or interacting 
factors along genes can then be quantitatively mapped to DNA regions. This mapping can 
either be performed for single genes by quantitative real-time PCR (qPCR) or genome-wide 
by ChIP-on-chip using microarray hybridization (chapter 6.2.7). 
By selectively inhibiting the four canonical CTD kinases Bur1, Ctk1, Kin28 and Srb10, 
followed by single-gene ChIP analysis of Tyr1 phosphorylation levels before and after 
inhibition, we analyzed these enzymes for their phosphorylation activity on Tyr1 in vivo 
(chapter 2.2). A candidate list of 15 kinases was also screened for changes in Tyr1 
phosphorylation levels by comparing either wild-type with kinase deletion strain (chapter 
2.3.1) or untreated with conditionally kinase-depleted strain (chapter 2.3.2).  
For the phosphatase search we took a slightly different approach. As the Tyr1 
phosphorylation signal strongly decreases before the pA site in the 3’ region, we found two 
likely candidate phosphatases within the CPF. One enzyme, Ssu72, has already been shown to 
function as a CTD phosphatase (56), whereas the second candidate, Glc7, has never been 
implicated in CTD dephosphorylation. By dephosphorylating phospho-Pol II with purified 
CPF in vitro and genome-wide ChIP of Tyr1-P in a candidate anchor-away strain in vivo, we 
aimed for identification of a Tyr1-P phosphatase (chapters 3.1, 3.2). By genome-wide ChIP of 
termination factors in this candidate anchor-away strain, we were able to characterize the role 
of Tyr1-P in transcription termination (chapter 3.4). 
Another repetitive element within a protein that was shown to play a regulatory role in 
transcription is the Spt5 CTR (86, 123, 124). It shows a repeat structure similar to Pol II CTD, 
can also be phosphorylated and recruits factors to Spt5 and Pol II in a phosphorylation-
dependent manner (87). Furthermore, the elongation factor Spt5 colocalizes with Pol II along 
the complete coding region of genes and past the pA site (43). Therefore, we asked whether 
more transcription-related proteins can be found that are recruited via the CTR and in which 
part of the transcription cycle they are important. We addressed these questions by single-
gene ChIP of transcription and RNA processing factors in wild-type and Spt5 ΔCTR strains 
and analyzed the profiles for changes in recruitment of these factors (chapter 4.2). 
Additionally, we characterized CTR interactions with recruited factors in vitro (chapter 4.3) 
and analyzed functional implications of recruitment defects. 
2. Towards the identification of the CTD Tyr1 kinase in yeast 
18 
 
2. Towards the identification of the CTD Tyr1 kinase in yeast 
Results presented in chapter 2.2 are published in (44). Detailed author contributions are listed 
on page IV. 
Mayer et al. reported that the CTD of yeast can be phosphorylated at position Tyr1, which 
extends the CTD code of Ser2 and Ser5 phosphorylation (chapter 1.4.4, (44)). The responsible 
kinase remains unknown. In human, c-Abl is known to phosphorylate Tyr1 in vitro (Figure 5, 
(157)), but this kinase does not have a homolog in yeast.  
Tyrosine residues are generally phosphorylated by typical tyrosine kinases or by dual-
specificity kinases (167). The following chapters present an overview of protein kinases in 
yeast (chapter 2.1), show published ChIP data of CTD phosphorylation signals in strains with 
inhibited canonical CTD kinases (chapter 2.2) and unpublished ChIP data of CTD 
phosphorylation signals in strains with 15 other deleted or conditionally depleted kinases 
(chapter 2.3). 
2.1. Protein kinases in yeast 
The yeast genome contains 129 protein kinases classified in 7 groups (http://www. 
yeastkinome.com/, (168, 169)). Kinases are one of the largest groups of proteins and 
constitute around 2% of the eukaryotic genome (169). They can be subdivided into different 
kinase groups which are generally conserved among eukaryotic organisms but there are also 
subfamilies specific for yeast (169). These kinases mostly play a role in functions especially 
important for unicellular organisms like nutrient uptake, pseudohyphal growth (170), stress 
responses, cell wall signaling, cell cycle or small-molecule transport (169, 171). Table 3 gives 
an overview of the 7 kinase groups in yeast. Enzymes are grouped according to structural 
similarities (168, 169). 
Table 3: 7 kinase groups in S. cerevisiae (adapted from (169) and http://www.kinase.com). 
Kinase group Members Properties 
AGC 17 Named after members protein kinase A, G and C 
Atypical 13 No sequence similarity but kinase function  
CAMK 22 Calcium-Calmodulin dependent  
CK1 4 Casein kinase 1 group 
CMGC 23 Named after members CDK, MAPK, GSK3 and CLK1 
STE 14 MAP kinase cascade kinases 
Others 36 No strong similarities to the other groups  
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In comparison to multicellular organisms, S. cerevisiae does not have receptor-type protein 
kinases, possibly because cell-cell communication is only needed on a very basic level (170). 
Furthermore, no true protein-tyrosine kinase is present in yeast as these enzymes are mostly 
involved in signaling pathways (170). Therefore, the Pol II CTD Tyr1 kinase in yeast could be 
a Ser/Thr kinase with dual specificity, like for example members of the Wee1 or the MAP 
kinase kinase (MAPKK) family (170). Generally, Tyr1 specificity cannot be excluded for any 
Ser/Thr kinase before tested in vitro (170). 
However, with 129 kinases already known and possibly more unconventional enzymes being 
discovered in the future, it is necessary to systematically search for the specific CTD Tyr1 
kinase. As a consequence, we decided to first test the four canonical yeast CTD kinases. 
2.2. Tyr1 of the Pol II CTD is not phosphorylated by canonical CTD kinases 
It was tested whether CTD Tyr1 phosphorylation depends on one of the yeast CTD kinases 
Kin28, Srb10, Bur1, or Ctk1, which correspond to human Cdk7, Cdk8, Cdk9, and Cdk12, 
respectively (48). Therefore, ChIP of CTD phosphorylations on single genes in catalytically 
inactive kinase mutant strains was performed. The respective kinases in these analog-sensitive 
(as) strains are mutated in their ATP binding pocket, where a bulky amino acid side chain is 
changed to the smaller glycine. This creates a new binding pocket that can be used by 
inhibitors, in this case pyrazolo[3,4-d]pyrimidine compounds (172). These inhibitors or a 
solvent control are added to yeast cultures 60 min before formaldehyde crosslinking 
(Methods) to inhibit kinase activity. ChIP experiments were performed using the Tyr1-P 
antibody as well as the phospho-specific antibody against the known CTD substrate (Ser2-P 
or Ser5-P) or the Rpb3 antibody as a control. Finally, qPCR was carried out using primers for 
two housekeeping genes, ADH1 and PMA1 (Figure 8).  
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Figure 8: CTD Tyr1 phosphorylation levels are not changed upon inhibition of the canonical Pol II CTD 
kinases.  
Kinase inhibition and ChIP experiments were performed with analog-sensitive yeast strains (as) (173). (a) 
Bur1as strain was inhibited with the small molecule inhibitor 3-MB-PP1, Ctk1as strain (b) and Srb10as strain (c) 
were inhibited with 1-NM-PP1, Kin28as strain (d) with 1-NA-PP1. ChIP occupancies of Pol II and of its 
different phosphorylated forms before and after kinase inhibition are indicated as black and gray bars, 
respectively. Results are shown for three different regions of the ADH1 and PMA1 gene. Fold enrichment values 
refer to a heterochromatic region on chromosome V that is not transcribed by Pol II. Standard deviations refer to 
at least two biological replicate measurements. 
Inhibition of a potential Tyr1 kinase in as strains should result in a decrease of the Tyr1-P 
signal compared to the untreated sample. According to Figure 8, however, this is not the case 
for inhibition of Bur1, Ctk1, Kin28 or Srb10: 
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Bur1 inhibition slightly reduces Ser2 phosphorylation levels at the coding region (ORF) of 
ADH1 (p-value: 0.02; T-test) and the 5’ region of PMA1 (p-value: 0.05) (Figure 8a, left 
panel). These results are in agreement with reported observations (60). Bur1 inhibition did not 
change Tyr1-P levels (Figure 8a, right panel). Ctk1 inhibition significantly reduces Ser2-P 
occupancy levels as expected (p-values ≤ 0.05) (Figure 8b, left panel), serving as a positive 
control, whereas Tyr1-P levels were not altered (Figure 8b, right panel). Srb10 inhibition 
neither changes Ser5-P occupancy levels nor the corresponding levels of Tyr1-P (Figure 8c). 
Kin28 inhibition leads to a reduction of Tyr1-P levels over the whole length of the transcribed 
region (Figure 8d, left panel). However, this was apparently due to an overall reduction of  
Pol II occupancy upon Kin28 inhibition as the ratios between Tyr1-P and Pol II subunit Rpb3 
ChIP occupancies do not change within the range of the standard deviation (Figure 8d, right 
panel). 
Taken together, inhibition of the four canonical CTD kinases in vivo did not significantly 
affect Tyr1 phosphorylation signals (Figure 8). This indicates that Tyr1 phosphorylation of 
the yeast CTD depends on a kinase other than the known CTD kinases. Consistent with this, 
Tyr1 phosphorylation in human cells is achieved by c-Abl (157), a kinase that lacks a yeast 
homolog. 
2.3. Systematical approach to identify the Tyr1 kinase 
The ChIP results above clearly indicate that Tyr1 is not phosphorylated by a known CTD 
kinase. To identify the kinase, a systematic search in a pool of kinase candidates in vivo 
seemed to be the most promising approach. The first candidates were chosen because of 
genetic or physical interaction with the transcription machinery, nuclear localization, or 
tyrosine kinase activity. Table 4 gives an overview of candidates, a short functional 
characterization and their relation to transcription or the Pol II CTD. This table does not 
include a complete list of possible Tyr1 kinases but rather a first selection: 
Table 4: Tyr1 kinase candidates. 
Kinase Group Function Relation to CTD 
Bck1 STE MEK-kinase (174), cell wall integrity 
signaling (175) 
genetic interaction with TFIID 
(176), Ctk1 (177) 
Bdf1 atypical localized uniformly along the length of 
chromosomes (178), two 
"bromodomains” (179) 
human homolog Brd4 
phosphorylates Ser2 (180) 
Cdc5* other functions in mitosis and cytokinesis 
(181) 
genetic interaction with Mex67 
(182) 
Cdk1/ 
Cdc28* 
CMGC catalytic subunit of the main cell cycle 
cyclin-dependent kinase (183) 
involved in CTD Ser5 
phosphorylation (55) 
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Kinase Group Function Relation to CTD 
Fus3 CMGC MAPK, control of cell proliferation 
(184) 
physical interaction with Pol II 
(185) 
Hrr25* CK1 involved in chromosome segregation 
(186); homolog of mammalian casein 
kinase 1delta (187) 
interaction with Ctk1 (177) and  
Pol II (188) 
Kns1 CMGC LAMMER family of protein kinases, 
dual specificity (189) 
unknown 
Kss1 CMGC MAPK, control of cell proliferation 
(184) 
physical interaction with Spt6 
(185), genetic with TFIID (190) 
Mck1 CMGC dual-specificity protein kinase related 
to mammalian GSK-3 family (191, 
192) 
genetic interaction with Pol II, 
TFIID, Paf1, Mediator (193) 
Mpk1 CMGC MAPK, mediates PKC signaling (175) physical interaction with Paf1 
complex (160) 
Pbs2 STE MAPKK, osmoregulatory signal 
transduction cascade (194) 
genetic interaction with Ctk1 (177), 
Pcf11 and Mediator (190) 
Snf1 CAMK phosphorylation of histone H3 (195) genetic interaction with Ctk1 (177), 
physical interaction with Gcn5 
(196) 
Swe1 other G2/M transition, inhibits Cdc28 
through phosphorylation of Y19 (197) 
physical interaction with TFIID 
(185), genetic interaction with Ccr4 
(198) 
Tpk1 AGC PKA catalytic subunit, nutrient 
response via the Ras-cAMP signaling 
pathway (199, 200) 
physical interaction with Spt5,  
Pol II (168)  
Yak1 CMGC serine-threonine protein kinase; 
component of a glucose-sensing 
system (201) 
physical interaction with Ess1, 
splicing factor Cdc40 (202) 
*essential genes 
Yeast strains were cloned that contained either knock-outs of the non-essential kinases or 
anchor-away tags for the essential enzymes (Table 6). Conditional depletion of a nuclear 
protein by the anchor-away technique works as described (203): An FRB tag is fused to the 
protein of interest in a strain that carries an FKBP12-tag on the ribosomal subunit Rpl13A. 
Upon rapamycin addition, the anchor forms a ternary complex with the FRB tag and 
rapamycin, which leads to export of this complex from the nucleus within a few minutes as 
ribosomal subunits are rapidly exported to the cytoplasm. Most of these strains die in presence 
of rapamycin. 
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ChIP experiments were performed with all kinase strains using the Tyr1-P and the Pol II 
(Rpb3) antibody serving as a control. Knock-out strains were compared to wild-type, anchor-
away strains were treated with rapamycin for 60 min before formaldehyde crosslinking and 
compared to DMSO treated cells (Methods). Chapters 2.3.1 and 2.3.2 provide an overview of 
the unpublished ChIP data for all kinase mutants. 
2.3.1. Non-essential kinases 
Kinase knock-out strains were analyzed by ChIP with the Tyr1-P and the Rpb3 antibody. 
Figure 9 depicts Tyr1-P occupancy levels in wild-type (wt) and 12 non-essential kinase 
knock-out strains normalized against total Pol II (Rpb3) levels. 
 
Figure 9: Tyr1-P occupancy levels are not decreased by deletion of 12 non-essential kinases.  
Tyr1-P occupancy relative to Rpb3 (Methods) is shown for wild-type (black bars) and 12 mutants. Results are 
shown for three different regions of the ADH1 and PMA1 gene. Standard deviations refer to at least two 
independent ChIP experiments. 
Deletion of a potential Tyr1 kinase should result in a decrease of the Tyr1-P signal in the 
mutant strain compared to the wild-type. According to Figure 9, however, this is not the case 
for 12 kinase deletions tested. Although the signals decrease slightly for some mutants, e.g. 
ΔSnf1 (brown bars), this decrease is within the range of the standard deviation for the wild-
type (black bars). For ΔBdf1 and ΔSwe1, a signal increase is detected, but the standard 
deviation is comparatively high. Taken together, the 12 kinases tested here are not identified 
as Tyr1 kinases.   
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2.3.2. Essential kinases 
FRB tags on essential kinase genes were cloned and validated as described (Methods).  
Figure 10 shows spot dilutions of Cdc5-, Cdk1-, and Hrr25-FRB strains on YPD and  
YPD + rapamycin plates. These spot dilutions were performed in order to verify the 
successful export of the FRB-tagged protein from the nucleus upon rapamycin treatment 
resulting in cell inviability. 
 
Figure 10: Growth analysis of anchor-away yeast strains. 
Serial dilutions of wild-type yeast and strains with FRB-tagged kinases Cdc5, Cdk1 and Hrr25 plated on YPD 
(left panel) and YPD + rapamycin (right panel) show that rapamycin is lethal for Cdc5-FRB and Cdk1-FRB but 
it has no effect on Hrr25-FRB and wild-type growth.  
To ensure that Hrr25 is exported from the nucleus, the protein was tagged with an additional 
GFP tag. Fluorescence microscopy pictures of the Hrr25-FRB-GFP strain without and with 
rapamycin are shown in Figure 11 (see Methods for experimental details). 
 
Figure 11: Fluorescence microscopy of the Hrr25-FRB-GFP strain. 
without (left) and with rapamycin (Rapa) (right) shows that Hrr25 is exported from the nucleus upon rapamycin 
addition. 
The fact that export of Hrr25 (Figure 11) from the nucleus is not lethal for the cells  
(Figure 10) possibly indicates that Hrr25 does not execute its essential function in the nucleus. 
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Figure 12 depicts Tyr1-P occupancy levels normalized against total Pol II (Rpb3) in the three 
essential kinase strains treated either with DMSO or rapamycin. 
 
Figure 12: Tyr1-P levels in Cdc5, Cdk1 and Hrr25 anchor-away strains are not influenced by rapamycin 
treatment.  
Tyr1-P occupancy relative to Rpb3 (Methods) is shown for untreated (-, dark bars) and treated samples (+, light 
bars). Results are shown for three different regions of the ADH1 and PMA1 gene.  Standard deviations refer to 
two independent ChIP experiments for Cdc5-FRB, three for Hrr25-FRB and 11 for Cdk1-FRB. 
Removal of a potential Tyr1 kinase from the nucleus by rapamycin treatment should result in 
a decrease of the Tyr1-P signal compared to the untreated sample. According to Figure 12, 
this is not the case for Cdk1 and Hrr25. For Cdc5, a slight decrease can be detected in the 
PMA1 ORF region. A genome-wide Tyr1-P profile should clarify if this is a widespread 
effect. Taken together, the three enzymes tested here cannot be identified as Tyr1 kinases.  
2.4. Discussion 
20 years ago it was shown that the mammalian kinase c-Abl can phosphorylate the CTD on 
tyrosine both in vivo and in vitro (62). However, this enzyme does not have a homolog in  
S. cerevisiae. Jeronimo et al. tested the well-known CTD kinases and other potential 
candidates but could not observe kinase activity on Tyr1 in yeast (47).  
The results shown here also demonstrate that inhibition of the canonical CTD kinases does 
not decrease Tyr1-P signals in vivo. Furthermore, deletion or conditional depletion of 15 other 
kinase candidates does not negatively influence Tyr1-P profiles. Although the results 
presented here generally confirm published data (47), they can be interpreted in different 
ways. Most probably all these enzymes tested are de facto not phosphorylating Tyr1 in vivo. 
However, there are also other possibilities: Another enzyme could compensate the 
deletion/depletion of the kinase, indicating more than one Tyr1 kinase. Alternatively, the 
deleted/depleted kinase could have only a slight effect on Tyr1 of the CTD, which cannot be 
detected by quantifying Tyr1-P levels on single-genes. Furthermore, indirect effects caused by 
deletion/depletion of a kinase which has other substrates than the CTD could influence the 
complete transcription process. This situation renders the data difficult to interpret.  
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To clarify these issues, Tyr1-P signals in the kinase mutants could be analyzed genome-wide. 
If none of the kinases influences Tyr1-P levels on a genome-wide scale, the candidate list 
would have to be extended. Another completely different approach could be to test purified  
S. cerevisiae kinases on a CTD substrate in vitro. 
In summary, from our current point of view, although having tested 19 different kinases we 
cannot identify the Tyr1 kinase. Thus, it becomes increasingly likely, that the Tyr1 kinase is 
an enzyme that has not been mentioned in relation to transcription so far (47).  
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3. Pol II termination involves CTD Tyr1 dephosphorylation by CPF 
subunit Glc7 
All results presented in chapter 3 were obtained in collaboration with Ashley Easter and Lori 
Passmore and are in the process of being published. For detailed author contributions see  
page IV. 
As explained in chapter 1.4.3, Tyr1 phosphorylation prevents premature recruitment of 
termination factors within gene bodies (44). At the pA site, Tyr1 phosphorylation levels drop, 
whereas Ser2 phosphorylation remains, apparently enabling termination factor recruitment 
(44). Thus, the transition from transcription elongation to termination involves CTD Tyr1 
dephosphorylation by an unknown phosphatase. We reasoned that the Tyr1 phosphatase 
might be part of the mRNA 3-end processing and termination machinery. In particular, CPF 
contains two candidate phosphatases, Ssu72 (56, 204) and Glc7 (153). Ssu72 can 
dephosphorylate CTD residue Ser5 (56, 61, 205). Glc7 plays a role in transcription 
termination on snoRNA genes (206) but has no known CTD-related activity. Here, we show 
that Glc7 is a Tyr1 phosphatase both in vitro and in vivo. We further show that Glc7 is 
required for recruitment of termination factors and for normal Pol II termination in vivo. 
3.1. CPF subunit Glc7 dephosphorylates CTD Tyr1 in vitro 
To investigate whether Ssu72 or Glc7 has CTD Tyr1 phosphatase activity we purified 
endogenous CPF from yeast. Analysis of the entire CPF complex was necessary since isolated 
phosphatases generally have little specificity, and target-specific dephosphorylation often 
relies on cofactors (207). The resulting preparations contained all CPF subunits, including 
Ssu72 and Glc7 (Figure 13a). To test CPF preparations for CTD phosphatase activity, we 
used a substrate of purified yeast Pol II that had been pre-phosphorylated on Tyr1, Ser2, and 
Ser5 (Methods; Figure 13b, lane 1). Incubation with CPF led to almost complete dephos-
phorylation of Tyr1, Ser2 and Ser5, as revealed by Western blotting (Figure 13b, lanes 3-5).  
To identify which of the two CPF phosphatases was responsible for Tyr1 dephosphorylation, 
we specifically inhibited Glc7 with EDTA or microcystin. EDTA chelates metal ions and 
abolishes activity of the metal ion-dependent phosphatase Glc7 (208, 209), but does not affect 
Ssu72 activity, which is metal ion-independent (204). Microcystin is a bacterial toxin that 
specifically inhibits PP1 and PP2A-type phosphatases (207) including Glc7, but not Ssu72. 
Addition of 10 mM EDTA or 200 nM microcystin to the reaction selectively inhibited Tyr1 
and Ser2 dephosphorylation, whereas Ser5 dephosphorylation was still observed (Figure 13b, 
lanes 6-13). These results show that the Glc7 subunit of CPF functions as a CTD phosphatase 
for Tyr1 and Ser2 in vitro. 
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Figure 13: CPF subunit Glc7 is a Pol II CTD Tyr1 phosphatase in vitro. 
(a) SDS-PAGE analysis of purified yeast CPF. An asterisk marks the tagged protein Ref2. Identities of bands 
were confirmed by mass spectrometry. (b) CPF dephosphorylates Pol II at CTD residues Tyr1, Ser2 and Ser5 
(lanes 3-5) in vitro as shown by Western blotting with antibodies against Pol II subunit Rpb3 and Tyr1-, Ser2- 
and Ser5-phosphorylated CTD (3D12, 3E10, and 3E8, respectively). The molar ratio of CPF to Pol II was 1:4, 
i.e. 1:104 of CPF to each Pol II CTD heptad. Specific Glc7 inhibition by 10 mM EDTA or 200 nM microcystin 
(lanes 7-9 or 11-13, respectively) selectively abolishes Tyr1 and Ser2 dephosphorylation by CPF. 
3.2. Glc7 is required for Tyr1 dephosphorylation in vivo 
To investigate whether Glc7 acts as a CTD phosphatase in vivo, we depleted Glc7 from the 
nucleus using the anchor-away method (203) (Figure 17a) and monitored changes in genome-
wide occupancy of Tyr1- and Ser2-phosphorylated Pol II by ChIP profiling (43). For 
metagene analysis of ChIP-chip data, we aligned genes at their pA sites and excluded genes 
flanked by a neighboring gene within 400 bp downstream of their pA site. This showed that 
nuclear depletion of Glc7 with rapamycin led to a defect in Tyr1 dephosphorylation at the pA 
site (Figure 15a). In addition, Tyr1 phosphorylation levels were increased around the TSS 
(Figure 16). The defect in Tyr1 dephosphorylation was also observed on individual genes 
(Figure 15b), and was not due to treatment with rapamycin (Figure 14). 
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Figure 14: Genome-wide ChIP occupancy of Tyr1-phosphorylated Pol II around the pA site is not 
influenced by rapamycin in wild-type yeast. 
ChIP-chip occupancy profiling of Tyr1-phosphorylated Pol II over 619 genes aligned at the pA site (dashed line) 
and normalized against the corresponding Rpb3 profile without and with rapamycin (-/+ Rapa, violet line and 
violet dotted line, respectively). The profile in a region from 400 bp upstream to 400 bp downstream of the 
polyA site is shown. 
Nuclear depletion of Glc7 specifically affected Tyr1 dephosphorylation and not Ser2 
dephosphorylation. ChIP occupancy of Ser2-phosphorylated Pol II normalized against total 
Pol II occupancy revealed no changes around the pA site (Figure 15d), whereas occupancy of 
Tyr1-phosphorylated Pol II increased (Figure 15c). Thus, the Glc7-dependent Ser2 
dephosphorylation observed in vitro (Figure 13b) is likely non-specific and not used in vivo, 
consistent with the previously observed Ser2 dephosphorylation by Fcp1 in vivo (59, 61). 
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Figure 15: Glc7 is required for Tyr1 dephosphorylation in vivo. 
(a) Metagene analysis for genome-wide ChIP occupancy of Tyr1-phosphorylated Pol II around pA sites in the 
Glc7 anchor-away strain. Experiments were performed in biological duplicates and ChIP-chip signals averaged 
by taking the median signal (log2 (IP/input)) at each genomic position over a set of 619 representative genes 
(Methods). To better visualize changes in Tyr1 dephosphorylation around the pA site relative to the region 
upstream, the data were further normalized to have approximately equal occupancy levels upstream (around  
-400 bp) of the pA site for the ‘–‘ and ‘+’ rapamycin treated profiles. Corresponding non-normalized data 
averaged over the entire gene length are shown in Figure 16. Occupancy of Tyr1-phosphorylated Pol II decreases 
sharply at the pA site (- Rapa, violet line), but Glc7 depletion largely abolishes this decrease (+ Rapa, violet 
dotted line). (b) Tyr1-P levels normalized to total Pol II (Figure 19a) on selected genes. Profiles represent 
normalized occupancies smoothed by a 150-nt window running median. Grey boxes indicate transcripts on the 
Watson (top) and Crick strands (bottom). (c, d) Depletion of Glc7 from the nucleus leads to a defect in Tyr1-P 
dephosphorylation but not in Ser2-P dephosphorylation. ChIP-chip occupancy profiling of Tyr1- (c) and Ser2- 
(d) phosphorylated Pol II over 619 genes aligned at the pA site (dashed line) and normalized against the 
corresponding Rpb3 profile without and with rapamycin (solid and dotted line, respectively). The profiles in a 
region from 400 bp upstream to 400 bp downstream of the polyA site are shown.  
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Figure 16: Depletion of Glc7 from the nucleus leads to a defect in Tyr1-P dephosphorylation. 
ChIP-chip occupancy profiling of Tyr1-phosphorylated Pol II over 619 genes without and with rapamycin  
(-/+ Rapa, solid and dotted line, respectively) is shown (also see Figure 15a). Profiles in a region from 250 bp 
upstream of the TSS to 400 bp downstream of the pA site are shown. The higher level of Tyr1-P in the 
rapamycin treated sample around the TSS is probably caused by newly initiating Pol II that still contains 
remaining Tyr1-P from the previous round of transcription or from Pol II readthrough from upstream genes after 
failure to terminate. 
To check whether the role of Glc7 in the nucleus is dependent on its catalytic activity, we 
transformed rescue plasmids expressing either wild-type or catalytically inactive mutants 
D94A or H247N of Glc7 into the Glc7 anchor-away strain. These mutations in the catalytic 
site are predicted not to disrupt the structure of Glc7 (209-211). Only wild-type Glc7 restored 
growth on rapamycin (Figure 18a), demonstrating that the catalytic activity of Glc7 is 
required for its nuclear function. 
Although the mammalian homolog of Glc7, protein phosphatase 1 (PP1), acts primarily on 
phosphorylated serine and threonine residues (207, 211), the recombinant enzyme is active on 
phosphorylated tyrosine residues (212). Tyrosine dephosphorylation can also be performed by 
the related Arabidopsis PPP-Kelch phosphatase BSU1 (213, 214) and the serine/threonine 
protein phosphatase 2A (PP2A) if activated by the correct binding partner (215). Our results 
for Glc7 demonstrate that a PP1 homolog can act on a natural phosphorylated tyrosine 
substrate when present in the context of the correct multiprotein complex - in this case, CPF. 
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3.3. Ssu72 does not dephosphorylate Tyr1 
As previously predicted (56, 204), Ssu72 was recently shown to contain a protein tyrosine 
phosphatase fold (205), but it apparently acts as a serine-specific phosphatase. Indeed, 
recombinant human Ssu72 was able to dephosphorylate Ser5 but neither Tyr1 nor Ser2 in 
vitro (Figure 18b). This is consistent with previous reports that Ssu72 is a CTD Ser5 
phosphatase (56, 61, 205). To investigate whether indeed Ssu72 does not dephosphorylate 
Tyr1 in vivo, we prepared an Ssu72-FRB anchor-away yeast strain and depleted Ssu72 from 
the nucleus by rapamycin addition. ChIP-chip experiments after Ssu72 nuclear depletion 
showed that Tyr1 dephosphorylation at the pA site was not influenced (Figure 18c), 
suggesting that Glc7 remained in the nucleus and dephosphorylated Tyr1 normally. To show 
this, we tagged Glc7 with mCherry in the Ssu72-FRB strain, and found that the localization of 
Glc7 was not influenced by rapamycin addition (Figure 17b).  
 
Figure 17: Growth analysis and fluorescence microscopy of anchor-away yeast strains. 
(a) Serial dilutions of wild-type yeast and strains with FRB-tagged phosphatases Glc7 and Ssu72 plated on YPD 
(left panel) and YPD + rapamycin (right panel) show that rapamycin is lethal for Glc7-FRB and Ssu72-FRB but 
it has no effect on wild-type growth. (b) Fluorescence microscopy of fixed cells of the Ssu72-FRB/Glc7mCherry 
strain shows that Glc7 is located in both cytoplasm and nucleus (left panel). This distribution does not change 
when rapamycin (Rapa) is added to the cells (lower panel). DAPI stain is shown as a control (right panel). 
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These results are consistent with a previous report that a point mutation in the CPF subunit 
Ref2 leads to Glc7 dissociation but has no impact on the integrity of the remaining complex 
(206). Taken together, these results indicate that Glc7 or Ssu72 can be depleted from CPF 
without destabilizing the complex, and that Glc7 catalyzes Tyr1 dephosphorylation, whereas 
Ssu72 does not. 
 
Figure 18: The catalytic activity of Glc7 in the nucleus is essential for cell viability and Ssu72 does not 
change Tyr1 phosphorylation in vitro and in vivo. 
(a) Serial dilutions of the Glc7-FRB anchor-away strain transformed with either empty p415-GAL-S vector or 
the same vector with galactose-inducible wild-type (wt), D94A or H247N catalytic mutants of Glc7 were plated 
on -leucine plates containing glucose (left panel), galactose (middle panel) or galactose with additional 
rapamycin (right panel). Only wild-type Glc7 can recover wild-type growth upon depletion of Glc7-FRB from 
the nucleus. (b) Ssu72 does not dephosphorylate Tyr1-P in vitro: human Ssu72 (hSsu72) dephosphorylates Pol II 
at CTD residue Ser5 but not at residues Tyr1 and Ser2 (lanes 2-4) as shown by Western blotting with antibodies 
against Pol II subunit Rpb3 and Tyr1-, Ser2- and Ser5-phosphorylated CTD (3D12, 3E10 and 3E8, respectively). 
A 7- to 37-fold excess of hSsu72, i.e. a molar ratio of 0.27 to 1.42 of hSsu72 to each Pol II CTD heptad, was 
incubated with Pol II for 2 h. (c) Depletion of Ssu72 from the nucleus does not change Tyr1-P levels in vivo: 
ChIP-chip occupancy profiling of Tyr1-phosphorylated Pol II over 619 genes aligned at the pA site (dashed line) 
and normalized against the corresponding Rpb3 profile without and with rapamycin (-/+ Rapa, solid and dotted 
line, respectively). Profiles in a region from 400 bp upstream to 400 bp downstream of the polyA site are shown. 
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3.4. Glc7 is involved in transcription termination 
Additional ChIP data indicated that Glc7 is required for transcription termination. The ChIP 
signal for total Pol II (Rpb3 subunit) normally decreases about 200 bp downstream of the pA 
site, due to transcription termination and Pol II release from DNA (Figure 19a, black line). 
Upon nuclear depletion of Glc7 however, strong Pol II ChIP signals remained further 
downstream (Figure 19a, dotted black line). These data suggest that Glc7 acts globally and is 
required for effective CTD Tyr1 dephosphorylation and normal transcription termination in 
vivo.  
To investigate whether Tyr1 dephosphorylation is required for normal termination factor 
recruitment, we determined Pcf11 and Rtt103 ChIP-chip occupancy after Glc7 nuclear 
depletion (Figure 19b). These experiments revealed a strong decrease in termination factor 
occupancy. Both Pcf11 and Rtt103 showed much lower occupancies downstream of the pA 
site after rapamycin addition (Figure 19b). These data indicate that the defect in Pol II 
termination (Figure 19a) results from a defect in termination factor recruitment. 
3.5. Discussion 
Whereas previous work showed that the Pol II CTD is phosphorylated at Tyr1, and that Tyr1 
phosphorylation impairs binding of transcription termination factors (44), it remained 
unknown whether Tyr1 dephosphorylation is required for termination in vivo and which 
enzyme dephosphorylates Tyr1. Here we establish the CPF subunit Glc7 as the CTD Tyr1 
phosphatase, and show that Tyr1 dephosphorylation is required for normal recruitment of 
termination factors and transcription termination. These results support the previously 
proposed “extended CTD code” for the coordination of factor recruitment during the 
transcription cycle (44) and indicate a crucial role for Tyr1 dephosphorylation in the 
elongation-termination transition. 
The data presented here and previously (44) thus lead to the following model for the 
elongation-termination transition of Pol II at the 3’-ends of protein-coding genes (Figure 19c). 
Elongating Pol II is phosphorylated mainly at Tyr1 (Y1P) and Ser2 (S2P), and this facilitates 
elongation factor binding. Tyr1 phosphorylation impairs premature recruitment of termination 
factors. When Pol II reaches the pA site, the Glc7 subunit of CPF dephosphorylates Tyr1, 
whereas Ser2 phosphorylation levels remain high. This allows for the binding of Pcf11 and 
Rtt103, termination factors that are not part of CPF and show peak occupancy ~100 bp 
downstream of the pA site (44). Further downstream, transcription terminates and Pol II is 
released from genes. When Glc7 is depleted from the nucleus, Tyr1 phosphorylation levels 
remain high downstream of the pA site, impairing termination and Pol II release. 
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Figure 19: Tyr1 dephosphorylation by Glc7 is required for full termination factor recruitment and 
transcription termination in vivo. 
(a) Metagene analysis for genome-wide ChIP occupancy of total Pol II (subunit Rpb3) around pA sites in the 
Glc7 anchor-away strain. Experiments were performed in biological duplicates and ChIP-chip signals averaged 
by taking the median signal (log2 (IP/input)) at each genomic position over a set of 619 representative genes 
(Methods). We further normalized the data to have approximately equal occupancy levels upstream (around  
-400 bp) of the pA site for the ‘-‘ and ‘+’ rapamycin treated profiles (see also legend Figure 15a). Occupancy of 
Pol II (Rpb3) decreases downstream of the pA site, indicating transcription termination (- Rapa, black line). 
Nuclear depletion of Glc7 impairs termination (+Rapa, black dotted line). (b) ChIP-chip occupancy profiling of 
TAP-tagged Pcf11 (top) and Rtt103 (bottom) in the Glc7 anchor-away strain. Experiments were performed in 
biological duplicates and ChIP-chip signals averaged by taking the median signal (log2 (IP/input)) at each 
genomic position over a set of representative medium length genes (1238 ± 300 bp, n = 339, see Methods). 
Occupancies of termination factors peak ~100 bp downstream of the pA site (- Rapa, grey and red lines), but 
Glc7 depletion largely decreases the peak signals (+ Rapa, dotted grey and red lines). (c) Model for the Pol II 
elongation-termination transition. DNA and RNA are depicted as grey lines, Pol II and its CTD are in black; 
Ser2-P is blue and Tyr1-P is purple. For details see within text. 
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In addition, we observed an influence of Glc7 depletion on Tyr1 phosphorylation levels near 
the TSS (Figure 16). This may be explained by initiation with polymerases that remained 
partially phosphorylated on Tyr1 residues, by termination defects at upstream genes (153), or 
by a possible role of Glc7 in transcription attenuation, which would be consistent with the role 
of Glc7 in Nrd1-dependent termination of snoRNA genes (206). 
Our results also provide evidence that pA-dependent 3’-pre-mRNA processing is coupled to 
transcription termination via CPF-triggered Pol II dephosphorylation. A link between the pA 
site and transcription termination was established over 25 years ago (130). In the “anti-
terminator model”, transcription of the pA site triggers a change in the Pol II machinery that 
allows for termination (14, 15, 128). In the “torpedo model”, pA-dependent RNA cleavage 
results in a new RNA 5’-end that is recognized by the Rat1/Rai1/Rtt103 exonuclease 
complex, which degrades nascent RNA and triggers termination (14, 15, 128). Our data are 
consistent with a combination of both models; Tyr1 phosphorylation would serve as an anti-
terminator that is removed at the pA site by Glc7, allowing for recruitment of termination 
factors, including the torpedo nuclease complex that contains Rtt103. 
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All results presented in chapter 4 were obtained in collaboration with Andreas Mayer and are 
published in (216). For detailed author contributions see page IV. 
Here we show that the Spt5 CTR is required for normal recruitment of CFI to the 3’-ends of 
yeast genes in vivo and interacts with CFI in vitro. High-resolution genome-wide occupancy 
profiling of CFI subunits reveals peak occupancy levels around 100 bp downstream of the pA 
site. Our results indicate that the Spt5 CTR cooperates with nascent RNA and the Ser2-
phosphorylated form of the Pol II CTD to recruit CFI to the 3’-ends of genes. 
4.1. Investigation of elongation factor recruitment by Spt5 CTR 
To investigate whether the function of the yeast Spt5 CTR in recruiting Pol II-associated 
factors extends to elongation factors other than Paf1 (86, 87), we carried out ChIP analysis in 
strains lacking the Spt5 CTR. We generated a yeast strain with a CTR deletion (Methods). As 
reported previously, CTR deletion led to 6-AU sensitivity and a slow-growth phenotype at 
16°C (Figure 20a) (86, 87). We also observed a slight growth defect at 30°C (Figure 20b), but 
not at 37°C (not shown). In contrast to observations in S. pombe (123), the morphology of  
S. cerevisiae was not altered upon CTR deletion (not shown). Quantitative Western blot 
analysis revealed approximately 1.7-fold higher Spt5 protein levels in cells lacking the CTR 
(Figure 20c).  
For ChIP analysis, we fused a tandem affinity purification (TAP) tag to the C-terminus of 
elongation factors in the CTR deletion background. The occupancy levels of the elongation 
factors were determined by ChIP at different positions of genes ADH1, ILV5, PDC1 and 
TEF1. We chose these genes for several reasons. First, these genes encode housekeeping 
proteins, are highly expressed (217), and are heavily occupied by Pol II in the mid-log phase 
of yeast growth (43). Second, their DNA elements, including the TSS and the pA site, are 
well characterized (10, 11, 105). Third, the transcription unit is long enough to distinguish 
between different binding levels at distinct positions of the gene. 
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Figure 20: Spt5 CTR deletion leads to a growth defect in the presence of 6-AU and to a slight increase in 
Spt5 protein levels.  
(a) The Spt5 ΔCTR mutant shows a strong growth defect in the presence of 50 µg/mL 6-AU as compared to 
wild-type. No effects are observed at 30°C or in the presence of 15 µg/mL mycophenolic acid (MPA) on solid 
medium. (b) The Spt5 ΔCTR mutant grown in liquid YPD medium (gray curve) shows a slight growth defect at 
30°C as compared to the wild-type (black curve). Standard deviations of three independent measurements are 
indicated for each data point. (c) Spt5 protein levels in the ΔCTR mutant are upregulated 1.7-fold compared to 
wild-type. Quantitative Western blotting was performed with antibodies against Spt5 and α-Tubulin. Different 
amounts of protein were loaded and quantification of the intensities was performed. Normalization of the  
Spt5/α-Tubulin ratio obtained for Spt5 ∆CTR cells against the corresponding ratio of wild-type cells revealed 
that Spt5 protein levels were slightly elevated (1.7 fold) in cells lacking the CTR of Spt5.  
We performed ChIP analyses for eight Pol II elongation factors that belong to the three 
different groups described recently (43): (i) Spt4 and Spt6 (group 1), (ii) Elf1 and Spn1 
(group 2), (iii) Bur1, Ctk1, Paf1 and Spt16 (group 3). The results are shown in Figure 22c 
(Paf1) and Figure 21. These data revealed strong factor binding at the ADH1 gene. A severe 
decrease in Paf1 occupancy to about 20% was detected at the ADH1 gene (Figure 22c), 
consistent with previous reports (86, 87) and providing a positive control. The difference in 
Paf1 occupancy was not due to a difference in Pol II occupancy, which was unaffected by 
CTR deletion (Figure 22c). However, the other representative elongation factors tested did not 
show significant differences in their gene occupancies (Figure 21), showing that CTR 
deletions specifically reduce gene occupancy of Paf1. 
4. The Spt5 C-terminal region recruits yeast 3' RNA cleavage factor I 
39 
 
 
Figure 21: Apart from Paf1 (Figure 22c) no other Pol II transcription elongation factors are affected by 
the deletion of the Spt5 CTR. 
Although Spn1 occupancy seems to be slightly reduced towards the 3’-end of the ADH1 gene in Spt5 ∆CTR 
cells as compared to wild-type cells, the differences are within the standard deviation and therefore are not 
significant. ChIP occupancies are indicated for wild-type and Spt5 ∆CTR cells as black and gray bars, 
respectively. The standard deviations refer to at least two independent ChIP experiments. 
4.2. Spt5 CTR is required for recruitment of CFI in vivo 
Since Spt5 colocalizes with 3’-end processing factors (43, 105, 107) and copurifies with these 
factors (115), we tested whether it plays a role in the recruitment of 3’-end processing and 
transcription termination factors. ChIP analysis revealed that all CFIA subunits Clp1, Pcf11, 
Rna14, and Rna15, showed high occupancy at the 3’-end of protein-coding genes and the pA 
site (Figure 22a and Figure 23). In Spt5 ∆CTR cells, occupancy of Clp1, Rna14, and Rna15 
was reduced more than 50% at the ADH1 gene, and also markedly lower at other genes tested 
(Figure 23). However, we observed no difference in the occupancy of Pcf11 between wild-
type yeast and Spt5 ∆CTR cells (Figure 22a).  
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Figure 22: ChIP analysis reveals that CFI occupancy is reduced in Spt5 ∆CTR cells. 
This is true for (a) CFIA subunits, except for Pcf11, as well as for (b) CFIB/Hrp1. (c) Whereas ChIP occupancy 
of Paf1 is strongly reduced in Spt5 ∆CTR cells, Pol II levels are not affected. (d) Pap1 occupancy is not changed 
in Spt5 ∆CTR cells. The fold enrichments at the ADH1 gene over a nontranscribed region that is located near the 
centromere of chromosome V are given for the TSS, the ORF region, the pA site, and for the region 3’ of the pA 
site. The color code is as in Figure 21. The standard deviations refer to at least two independent ChIP 
experiments. 
Since CFIA is associated with CFIB/Hrp1, we investigated whether Hrp1 occupancy was 
affected by CTR deletion. Previous ChIP analyses have shown that Hrp1 crosslinks 
throughout the coding regions until the 3’-end of genes (50, 105). Our ChIP analysis revealed 
that Hrp1 shows strongest occupancy near the pA site, although it is recruited earlier than 
CFIA subunits (Figure 22b). Similar to CFIA subunits, Hrp1 binding was markedly reduced 
in Spt5 ∆CTR cells (Figure 22b). However, no occupancy difference could be observed for 
the poly(A) polymerase Pap1 (Figure 22d), which is also required for 3’-end processing (137, 
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218). Taken together, the Spt5 CTR plays a crucial role in recruitment of CFI, but not of 
Pap1, to the 3’-end of protein-coding genes. 
 
Figure 23: Rna15 ChIP occupancy levels at ILV5, PDC1 and TEF1 genes are also reduced in Spt5 ∆CTR 
cells.  
The Rna15 occupancy levels are indicated for the promoter (prom) and ORF regions as well as for the pA site of 
all three genes in wild-type (black bars) and Spt5 ∆CTR cells (gray bars). The color code is as in Figure 21. The 
standard deviations refer to at least two independent ChIP experiments. 
4.3. Spt5 CTR interacts with CFI in vitro 
Since CFI recruitment to genes was impaired upon CTR deletion, we asked whether the Spt5 
CTR interacts with CFI in vitro. We performed pulldown experiments with a recombinantly 
expressed glutathione S-transferase (GST)-tagged version of the Spt5 CTR and yeast cell 
lysates prepared from strains that expressed TAP-tagged versions of CFI subunits. Western 
blot analysis of the eluates with antibodies directed against the GST tag and the TAP tag of 
the respective CFI subunit revealed a coprecipitation of the GST-tagged Spt5 CTR and the 
CFI subunits Rna14, Rna15, and Hrp1, which was not detected with GST alone (Figure 24). 
A coprecipitation could not be observed for Pcf11 (not shown), in agreement with the ChIP 
data that showed that Pcf11 occupancy is not altered in Spt5 ∆CTR cells (Figure 22a). For 
Clp1, the input signal in the Western Blot analysis was much lower compared to other CFI 
subunits, such that a possible interaction between the Spt5 CTR and Clp1 cannot be ruled out. 
Taken together, these pulldown experiments revealed a previously unobserved interaction 
between the Spt5 CTR and CFI in vitro. Since the interaction was detected with the use of a 
lysate that naturally contains many non-specific competitor proteins, and since it was not 
observed with the GST tag alone, it must be regarded as being highly specific. It is however 
possible that the interaction is mediated by other proteins in the extract and thus indirect. 
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Figure 24: The Spt5 CTR interacts with CFI subunits in vitro. 
GST pulldown experiments were performed with a GST-Spt5 CTR fusion protein (GST-CTR), with GST alone 
(GST) and without protein (-), serving as negative control. Western blotting was performed for the last washing 
fractions (W), the combined elution fractions (E) of the respective sample, and for 1% of the Rna14-TAP (first 
panel), Rna15-TAP (second panel), and Hrp1-TAP (third panel) yeast cell lysates (Input) with antibodies against 
the TAP tag of the corresponding CFI subunit and the GST tag (for details see Methods). The signals obtained 
for GST and GST-CTR were similar and are exemplarily shown for the pulldown experiments with Rna14-TAP 
(fourth panel). 
4.4. RNA contributes to CFI recruitment 
Since deletion of the Spt5 CTR led to a marked reduction in the occupancy of CFI subunits, 
but not to a complete loss, we asked which factors contribute to the residual binding of CFI. 
Since Rna15 and Hrp1 contain RNA recognition motifs (RRMs) that are known to bind RNA 
sequences in vitro (139, 219-221), we reasoned that nascent RNA may contribute to CFI 
recruitment. To address this, we performed an RNase-ChIP assay (222). In this assay, RNA is 
digested before the immunoprecipitation step, leading to a drop in factor occupancy if factor 
recruitment involves RNA. 
We performed RNase-ChIP for Rna14 and Rna15 (Figure 25). First, we observed a decrease 
in Rna15 occupancy after RNase treatment, indicating an important role of RNA in Rna15 
recruitment, both in wild-type and Spt5 ΔCTR cells. Second, Rna15 binding most strongly 
depended on RNA around the pA site of the ADH1 gene. Third, the strongest reduction in 
Rna15 occupancy was observed when both the Spt5 CTR was deleted and when RNA was 
removed by RNase treatment. The additional decrease of the Rna15 occupancy level was 
highly reproducible and could be observed in all four independent biological replicates. A 
similar RNA dependence could be observed for Rna14. These results indicate that RNA 
contributes to CFI recruitment in vivo and that this can explain residual recruitment of CFI in 
cells lacking the Spt5 CTR. 
4. The Spt5 C-terminal region recruits yeast 3' RNA cleavage factor I 
43 
 
 
Figure 25: RNase-ChIP assays reveal that RNA contributes to CFI recruitment in Spt5 ∆CTR cells. 
RNA-dependent binding is given for the ORF region, the pA site and a region 3’ of the pA site of the ADH1 
gene. The ChIP occupancy signal without RNase treatment (black) was set to 100%. The relative ChIP signals of 
Rna14 and Rna15 for wild-type (dark gray) and Spt5 ∆CTR cells (light gray) after RNase treatment are 
indicated. The corresponding percentages are given above the bars. The standard deviations were calculated 
from four independent experiments. 
4.5. CFI colocalizes with the Ser2-phosphorylated CTD downstream of the pA site 
It was shown for mammalian cells that homologs of the yeast CFI complex are already 
recruited at the promoter region of genes (223, 224). One study in yeast showed that some 
RNA 3’-end processing factors, including Rna14 and Rna15, also crosslinked to the promoter 
and the early coding region of the PMA1 gene, but not at other genes tested (105). However, 
our ChIP analysis (Figure 22 and Figure 23) and published data in yeast (105, 145) suggested 
that CFI subunits crosslinked near the pA site at the 3’-end of genes. 
To investigate the preferred location of CFI subunits on a genome-wide level, we performed 
ChIP-chip analysis for Rna14 and Rna15. This revealed CFI recruitment at all protein-coding 
genes that are occupied by Pol II and its elongation factors (43). The ChIP-chip profiles 
showed sharp occupancy peaks for Rna14 and Rna15 105 bp and 108 bp downstream of the 
pA site, respectively (Figure 26a). We also detected weak Rna14 and Rna15 binding over the 
transcribed region, with an increase towards the 3’-end. These profiles were independent of 
gene length (Figure 26a and Figure 27). Comparison with previous profiles (Figure 26a) (43) 
revealed that peak occupancies of Rna14 and Rna15 coincided with Pcf11 occupancy, which 
peaked 52 bp downstream of the pA site (Figure 26a). CFI subunit peak occupancies further 
occured in a region where the occupancies for Spt5 and the Ser2-phosphorylated Pol II were 
high (Figure 26b). The sharp occupancy drop of CFI subunits coincided with the drop for the 
ChIP signal of the Ser2-phosphorylated CTD, consistent with its role in CFI recruitment. 
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Figure 26: Genome-wide ChIP-chip occupancy profiling of CFI subunits, Ser2-P Pol II and Spt5 in yeast. 
(a) Gene-averaged profiles for the long gene length class (2,350 ± 750 bp, 299 genes, see Methods) for Pcf11 
(43), Rna14, and Rna15. Profiles of other length classes are generally similar (Figure 27). Dashed black lines 
indicate the TSS and pA site. (b) Gene-averaged profiles as in (a) for the transcription elongation factor Spt5 
(43) and the Ser2-phosphorylated CTD form of Pol II (43). Occupancies and signal intensities are given for Spt5 
and the Ser2-phosphorylated form of Pol II on the left and right y-axes, respectively. 
 
 
Figure 27: Genome-wide ChIP-chip occupancy profiling of CFI subunits in yeast for short and medium 
length genes. 
Gene-averaged profiles (a) for the short gene length class (512-937 bp, 266 genes, see Methods), (b) for the 
medium length class (938-1537 bp, 339 genes) for Pcf11 (43), Rna14, and Rna15. Dashed black lines indicate 
the TSS and pA site. 
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4.6. CTR deletion does not impair termination 
Previous studies showed that mutations in Pcf11, Rna14, and Rna15 can lead to defects in 
transcript cleavage and readthrough transcription beyond the termination site (225-227). We 
therefore investigated whether the reduced level of CFI recruitment observed in Spt5 ΔCTR 
cells leads to Pol II readthrough transcription at the ACT1, PMA1 and RNA14 genes. To detect 
transcriptional readthrough, we chose a PCR-based method with a gene-specific forward 
primer and different reverse primers positioned downstream of the normal transcript 
termination site, as described previously (146) (Figure 28a). In this assay, a prolonged 
transcript resulting from readthrough transcription would be detected by the generation of 
PCR products with a reverse primer that is located downstream of the termination site. As 
shown in Figure 28b, transcriptional readthrough could be detected when the function of 
Rna14 was impaired with the use of a temperature-sensitive yeast strain, serving as a positive 
control for this assay. However, no differences in the PCR products, and thus the length of the 
PMA1 transcripts, were observed between wild-type and ΔCTR cells (Figure 28b). Similar 
results were obtained for the ACT1 and RNA14 genes (not shown). Thus, deletion of the Spt5 
CTR does not result in a termination defect that would be detected by transcriptional 
readthrough. 
Although we did not detect readthrough transcription at tested single genes, it may still occur 
at other genes. To investigate this, we measured high-resolution ChIP-chip occupancy profiles 
for the Pol II core subunit Rpb3 in wild-type and mutant yeast cells lacking the CTR. The 
high correlation between the Pol II profiles (Pearson correlation coefficient R = 0.89) and the 
high similarity of the gene-averaged profiles (Figure 28c) however indicated no difference in 
Pol II occupancy between wild-type and mutant cells. In addition, a difference profile 
calculated from Rpb3 occupancy in ∆CTR and wild-type cells did not reveal any clusters of 
altered occupancy. These results show that transcription readthrough does not occur in the 
∆CTR strain. 
4. The Spt5 C-terminal region recruits yeast 3' RNA cleavage factor I 
46 
 
 
Figure 28: Spt5 CTR deletion provokes neither transcriptional readthrough of Pol II nor alternative pA 
site usage. 
(a) Schematic representation of the yeast PMA1 locus. The ORF region and the two pA sites according to (146) 
are indicated by a box and vertical arrows, respectively. The forward primer (fw) and two reverse primers (1rev 
and 2rev) that were used for Pol II readthrough detection are depicted as horizontal arrows. (b) Agarose 
gelelectrophoresis of the five PCR products as described in (a) for wild-type (wt), Spt5 ∆CTR cells (∆CTR) and 
the rna14-1 temperature sensitive strain grown at permissive (24°C) and restrictive temperature (37°C). The 
rna14-1 mutant led to a readthrough transcript at 37°C (1.5 kb, black arrow), and served as a positive control. No 
differences in the length of the PCR products could be detected between wild-type and Spt5 ∆CTR cells. The 
unspecific PCR product also obtained with the second reverse primer (2rev) is marked by an asterisk. The height 
of the marker lanes in base pairs (bp) are shown in lane 1. (c) Gene-averaged occupancy profiles as in Figure 26 
but for medium gene-length class (1,238 ± 300 bp, 339 genes, see Methods) of Pol II (Rpb3) in wild-type and 
Spt5 ∆CTR cells. (d) The nucleotide sequence of the 3’ region of yeast ACT1 is shown. Key sequence elements 
are labeled. Blue sequences are sites predicted by (228). 3’-RACE revealed three major pA sites (red filled 
boxes) and three minor pA sites (red frames) that were equally used in wild-type and Spt5 ΔCTR cells. 
Additionally, 3’-RACE also led to the mapping of three rare pA sites that were exclusively used in Spt5 ∆CTR 
cells (yellow boxes). For details see Methods. 
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4.7. CTR deletion does not alter pA site usage 
Since mutations of 3’-end processing factors were also shown to result in the usage of 
alternative pA sites (228), we investigated whether CTR deletion and the resulting reduction 
in CFI recruitment lead to alternative pA site usage. To detect a possible change in the usage 
of pA sites in vivo, we used rapid amplification of cDNA 3’-ends (3’-RACE), which allows 
the mapping of the 3’-ends of transcripts (229). We performed 3’-RACE for the ACT1 and 
PMA1 genes, which possess five and two pA sites, respectively (Figure 28d) (105, 228). The 
experiments revealed multiple pA sites for the ACT1 gene, which map to a distinct region at 
the 3’-end of the gene, 1508-1617 bp from the TSS. We also quantified the usage of the 
different pA sites by sequencing 25 PCR products from both wild-type and Spt5 ∆CTR clones 
(Methods). For ACT1, these experiments revealed three major pA sites that were used in 75% 
of the cases, and six minor pA sites (Figure 28d). However, no significant difference in pA 
site usage was detected between wild-type and Spt5 ΔCTR cells (Figure 28d). Similar results 
were obtained for the PMA1 gene (not shown). Thus, a reduced level of CFI recruitment in 
Spt5 ∆CTR cells does not lead to altered pA site usage in vivo. 
4.8. Discussion 
Two major transitions occur during the Pol II transcription cycle, the initiation-elongation 
transition at the 5’-ends of genes and the elongation-termination transition at the 3’-ends of 
genes, which is coupled to RNA processing. Whereas the first transition has been extensively 
studied (43, 50, 106, 163, 230-232), less is known about the second transition. Studies of the 
second transition revealed a role of the Ser2-phosphorylated Pol II CTD in the recruitment of 
3’-end processing and termination factors (65, 145-147, 163). This transition also involves the 
Paf1 complex (85, 233, 234), elongation factor Spt6 (235), and the transcription regulator 
Sin1 (236).  
Here we provide evidence for a role of the Spt5 CTR in the elongation-termination transition, 
in particular in the recruitment of the essential mRNA 3’-end processing factor CFI. ChIP 
analysis of wild-type and Spt5 ΔCTR in yeast cells detected a reduction in the occupancy of 
Paf1, as described previously (86, 87), but also of CFI subunits, indicating impaired CFI 
recruitment to the 3’-ends of genes in vivo. A pulldown assay additionally revealed an 
interaction between CFI subunits and the Spt5 CTR in vitro. This is consistent with a study 
showing that Rna14 can be copurified with Spt5 (115). RNase-ChIP experiments for CFI 
subunits Rna14 and Rna15 showed that RNA contributes to CFI recruitment in vivo. Genome-
wide profiling by ChIP-chip revealed a sharp peak in Rna14 and Rna15 occupancy ~100 bp 
downstream of the pA site, which coincides with high occupancy of Spt5 and the Ser2-
phosphorylated Pol II. These results show that the Spt5 CTR contributes to the recruitment of 
CFI to a defined region at the 3’-ends of yeast genes.  
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There is evidence that recruitment of RNA 3’-end processing factors also involves the Paf1 
complex. Deletion of subunits of the Paf1 complex reduces the recruitment of Pcf11 (233) and 
interferes with Pol II binding of Cft1 (234), a component of the yeast CPF complex. Since 
Paf1 occupancy levels are markedly reduced in Spt5 ΔCTR cells, it may be argued that 
recruitment of CFI may occur via the Paf1 complex and that the observed reduction in CFI 
subunit occupancy may result from a loss of the Paf1 complex. However, several lines of 
evidence argue against this model and instead argue that CFI recruitment occurs via a direct 
interaction with the CTR. First, Pcf11 occupancy is not altered in Spt5 ΔCTR cells, despite 
the loss of the Paf1 complex (Figure 22a, c). Second, despite extensive interactomics studies, 
physical interactions between the Paf1 complex and CFI have never been observed. Third, the 
Paf1 complex clearly dissociates from the Pol II elongation complex upstream of the pA site 
(43, 105, 237), whereas CFI subunits are mainly recruited downstream of the pA site  
(Figure 26a) (43, 105, 237). These results argue for a Paf1 complex-independent mechanism 
of CFI recruitment in yeast.  
We further showed that the Spt5 CTR is not required for normal pA site usage and 
transcription termination in vivo. This is consistent with the nonessential nature of the Spt5 
CTR in yeast and may be due to residual CFI recruitment in Spt5 ΔCTR cells that likely 
results from binding of the CFI subunits to RNA and from the binding of Pcf11 to the Pol II 
CTD. Pcf11 contains an essential CID domain, which directly binds the Ser2-phosphorylated 
CTD (65, 131, 145) and may be responsible for normal recruitment of Pcf11 to genes upon 
CTR deletion. These observations indicate that CFI is recruited to a defined region 
downstream of the pA site by simultaneous interactions with the Spt5 CTR, nascent RNA, 
and the Pol II CTD (Figure 29). This model is consistent with the reported binding of Rna14 
and Rna15 to the phosphorylated CTD (148) and with other published data. Rna15 can be 
crosslinked to RNA (139) and contains an RRM that binds GU-rich RNA (219, 220). Hrp1 
has two RRMs that bind to AU-containing RNAs (221).  
Finally, our results have implications for understanding the evolution of transcription-coupled 
events. Spt5 represents the only known RNA polymerase-associated factor that is conserved 
in all three domains of life (110); its bacterial homolog is called NusG (83). All Spt5 
homologs contain two conserved domains, the NGN domain and a C-terminal KOW domain 
(113). Whereas the NGN domain binds to the polymerase clamp domain and closes the active 
center cleft, apparently to render transcription processive, the KOW domain extends from the 
polymerase surface toward exiting RNA (84, 101, 112) (Figure 29). In bacteria, the KOW 
domain interacts with the ribosome, thus coupling transcription to mRNA translation (238, 
239). In eukaryotes, transcription and translation take place in different cellular 
compartments, and any coupling between these processes would likely occur via the mRNA 
that exits the nucleus (240, 241). Our data indicate that the CTR of Spt5 contributes to the 
coordination of transcription with RNA 3’-end processing, which in turn is coupled to mRNA 
export (242-244). Since the CTR occurs only in eukaryotic Spt5 homologs, it is likely that it 
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emerged during evolution to maintain coupling between transcription and translation after the 
spatial separation of these processes. Such coupling may be achieved by cotranscriptional 
Spt5-dependent loading of mRNA export factors onto the nascent RNA, before its maturation, 
nuclear export, and translation in the cytosol. 
 
Figure 29: Model of CFI recruitment in yeast. 
The complete yeast Pol II elongation complex with bound Spt4/5 is viewed from the back (84). Pol II and Spt4/5 
are shown as molecular surfaces with key domains highlighted in color and labeled. Exiting RNA, the  
C-terminal KOW domains, the CTR of Spt5, and the Pol II CTD all extend from Pol II around the Rpb4/7 
subcomplex, establishing a main interface for CFI recruitment. Rna14 may directly contact the Spt5 CTR, 
whereas the RNA is bound by the C-terminal RRM of Rna15 and by two internal RRMs of Hrp1. The Pol II 
CTD is bound by the N-terminal CID domain of Pcf11. CFI subunits are drawn to scale. Important protein 
domains are illustrated as extensions from the respective protein core. 
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5. Future perspectives 
Gene transcription in eukaryotes is not only an essential but also a very highly regulated 
process. Transitions from transcription initiation to elongation and from elongation to 
termination as well as all processes involved in RNA maturation have to be coordinated. 
Reversible phosphorylations of C-terminal protein repeat domains of Pol II and elongation 
factor Spt5 have proven to be very important in this process (14, 15, 60, 68, 86). This work 
contributed to a more detailed understanding of the extended CTD code including Ser2, Ser5 
and Tyr1 phosphorylation (44) and its role in transcription termination (chapter 3). Moreover, 
an additional function of the Spt5 CTR in CFIA recruitment was discovered (chapter 4). 
Although these findings greatly enhance our knowledge about principles underlying 
transcriptional regulation, still a lot of important questions are unanswered and will be 
discussed in the following chapters.  
5.1. The CTD code extension Tyr1-P 
The generation of monoclonal residue-specific phospho-CTD antibodies was an important 
development in the CTD research field. Only with such a specific tool was it possible to 
characterize the Tyr1 phosphorylation pattern on transcribed genes in yeast (44). Based on 
this genome-wide profile, this work could discover a regulatory function of Tyr1-P in 
transcription termination as well as the Tyr1-P phosphatase Glc7, revealing more details about 
the elongation-termination transition.  
The corresponding Tyr1 kinase remains to be identified (chapter 5.1.1). Moreover, the role of 
Tyr1-P in transcription termination is so far only a negative function as Tyr1-P prevents 
termination factor recruitment. Identification of the kinase could help to characterize a 
positive function of Tyr1-P (chapter 5.1.2). 
5.1.1. Identification of (the) Tyr1 kinase(s) 
As mentioned in chapter 2.4, the in vivo approach to identify kinases by deletion or 
conditional depletion of candidates could be continued by extending the candidate list  
(Table 4). Non-essential proteins could be deleted, essential proteins conditionally depleted by 
the anchor-away procedure (203) or inhibited chemically (172). Resulting yeast strains could 
then be analyzed by genome-wide ChIP of Tyr1-P and Rpb3 using ChIP-seq, where ChIP is 
coupled to high-throughput DNA sequencing (245). 
Another possible approach is fractionation of wild-type S. cerevisiae nuclear extracts and 
incubation of these fractions with unphosphorylated Pol II or synthetic unphosphorylated 
CTD peptides. The samples can then be analyzed by Western blotting or Enzyme-linked 
Immunosorbent Assay (ELISA) to compare Tyr1-P phosphorylation levels using the 3D12 
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antibody. Extract fractions leading to a Tyr1-P signal could then be fractionated further and 
analyzed by mass spectrometry (MS).  
Alternatively, kinase candidates could be purified in vitro and incubated either with 
unphosphorylated Pol II or CTD peptides. Tyr1-P signals would then be detected by Western 
blotting or ELISA as described above.  
5.1.2. A positive function of CTD Tyr1 phosphorylation 
The two phosphorylations of the initial CTD code, Ser5-P and Ser2-P, have two very special 
transcription related functions: Ser5-P is necessary for capping enzyme recruitment, therefore 
enabling 5’ RNA capping (50, 74). Ser2-P binds the termination factor Pcf11, thus recruiting 
the RNA 3’-end processing machinery (65, 128). Tyr1-P was identified as the third CTD code 
phosphorylation. It is possible that Tyr1-P has a positive function in transcription of similar 
importance.  
One approach to discover Tyr1-P functions could be to perform an interaction screen in which 
a Tyr1-P containing CTD peptide is used to pull down physical interactors from whole cell 
lysate. The unphosphorylated CTD peptide can be used as a control. MS could then analyze 
the pulldown fractions and identify Tyr1-P CTD binders. Whole cell lysates from different 
organisms, e.g. from yeast and human, can be tested with the same CTD peptide, opening up 
the possibility to characterize the function of Tyr1 phosphorylation in yeast and higher 
eukaryotes in parallel. Identified CTD interacting proteins could then be cocrystallized with a 
Tyr1-P peptide to characterize the binding interfaces. 
A possible role of Tyr1-P could lie in regulating cotranscriptional splicing (246), as the  
Tyr1-P signal increases along the coding region of genes. Moreover, splicing has not been 
linked to one specific CTD phosphorylation before. Binding studies with CTD peptides and 
splicing factor proteins should elucidate a possible correlation.  
A second approach relies on the identification of a Tyr1 kinase. Deletion or depletion of this 
enzyme in vivo enables the study of defects in this strain, which could be linked to the 
decrease in Tyr1 phosphorylation. If the enzyme is depleted conditionally e.g. in an anchor 
away strain, different time points after rapamycin treatment could be analyzed to determine 
the dynamics of involved processes. 
A parallel characterization of Tyr1-P functions in the human system could provide insights 
into evolution of this CTD phosphorylation from yeast to human. Although the Tyr1 residue 
is essential both in yeast and human, the coding region of genes, where Tyr1-P levels are 
high, differs greatly. The human genome contains longer and less closely packed genes and 
many of the human genes also carry very long introns (48, 247).  
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5.1.3. Characterization of Thr4 and Ser7 phosphorylation in yeast 
To complete the study of the CTD and its modifying phosphorylations in S. cerevisiae,  
Thr4-P and Ser7-P would have to be characterized as well. For Ser7-P the genome-wide 
profile was already published (43), but the function of this modification remains enigmatic. In 
the human system, Ser7-P contributes to recruitment of the Integrator complex involved in 
snRNA maturation (82). Mutation of Ser7 to Ala is not lethal (31, 35) in yeast, enabling 
cloning of a corresponding strain that could be examined for functional defects. 
Thr4 phosphorylation has not been extensively studied in yeast until now. Neither kinase nor 
phosphatase is known (Table 1) and the function remains ambiguous although the genome-
wide profile indicates an even distribution along the coding region of genes (44). The human 
Thr4 kinase Plk3 was recently identified and a function of Thr4-P in transcription elongation 
was implicated (38). Possible functions and modifying enzymes for Thr4-P in yeast could be 
found by similar approaches like for Tyr1-P (chapter 5.1.1 and 5.1.2) or by mutating all Thr4 
residues to Ala and analyzing functional defects in this strain. 
5.2. Towards an overall CTD phosphorylation pattern 
Reversible posttranslational phosphorylations of the CTD are read by proteins that are 
specifically recruited to these phosphorylations, which therefore are termed the “CTD code” 
(47, 68). This code has served as a model for the varying CTD phosphorylation patterns 
within one CTD molecule. However, it is so far unknown how these phosphorylations are 
distributed throughout the complete CTD.  
For characterization of the CTD phosphorylations, specific monoclonal antibodies are the best 
and widely used tools available at the moment. These antibodies are selected because of their 
specific recognition of epitopes on phosphorylated CTD peptides in vitro. The conditions in 
vivo, however, can be completely different. Only accessible epitopes are recognized by the 
antibodies but neighbouring phosphorylations or binding proteins can mask some of them. 
Thus, it is not clear how many phosphorylated epitopes really exist, only how many the 
antibody recognizes. Moreover, the antibodies cannot detect where on the CTD these 
modifications occur, how many times they can be found within one molecule or if the 
recognized phosphorylation depends on other modifications in the vicinity (48).  
To address all these questions experimentally, the best approach would be MS of the complete 
CTD. As this peptide is too large in one piece, it has to be cut into smaller fragments, which 
in turn could be subjected to MS. 
The experimental output could provide information about whether all possible residues within 
the CTD are phosphorylated (122 possible sites in S. cerevisiae), or how many residues within 
one repeat can be phosphorylated and in what combinations. Moreover, special 
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phosphorylated regions or phosphorylation patterns could be discovered. If such patterns can 
be found, synthetic peptides consisting of these phosphorylated sequences could be used for 
pulldown experiments to find specific interactors. 
This method, however, can only provide information about the complete population of Pol II 
molecules within a cell. Special pools of Pol II molecules could be isolated, e.g. by arresting 
cells in the cell cycle. Data from this experiment could help to characterize the coupling of 
transcription to the cell cycle.  
With the experiments mentioned above, the CTD code could be characterized in more detail. 
If the code for example changes along genes at defined positions, possible connections to the 
histone code in the same regions could be identified much easier. 
5.3. New functions of the Spt5 CTR  
It has been found in this and other studies that the C-terminal repeats of Spt5 can act as a 
recruitment platform for transcription and RNA processing factors similar to the Pol II CTD: 
The CTR is involved in recruitment of the 5’ RNA capping enzyme (75, 123). Upon 
phosphorylation by Bur1 kinase, the CTR binds the Paf1 complex during transcription 
elongation (86, 87). At the 3’ region of genes, the CTR contributes to CFIA recruitment 
(chapter 4). As a consequence, the question immediately arises if there are still additional 
transcription related factors to be identified that are recruited by the CTR of Spt5. New CTR 
interactors could be discovered by in vitro GST-CTR pulldown experiments using whole cell 
extracts. The binding fractions could be further analyzed by MS. 
This study showed that CFIA is partly recruited by the Spt5 CTR and partly by RNA  
(chapter 4). It would be interesting to characterize these interactions further. Which subunit of 
CFIA physically interacts with the CTR could be discovered by fluorescence anisotropy 
measurements of CFIA subunits with a fluorescently labeled CTR peptide. The RNA binding 
of CFIA could be characterized by PAR-CLIP to identify specific RNA sequences or regions 
that are bound by this complex (248). 
Additionally, the role of CTR phosphorylation in factor binding remains to be understood. It 
is known that the Paf1 complex is recruited in a phosphorylation dependent manner (86, 87) 
but this has not been tested for other proteins. If more factors are influenced by CTR 
phosphorylation, it is possible that a CTR phosphorylation cycle exists, leading to a “CTR 
code” similar to the known CTD code. This question could be addressed experimentally by 
generating monoclonal antibodies against a phosphorylated and an unphosphorylated CTR. 
ChIP using these antibodies could then provide insights into the CTR phosphorylation cycle. 
Comparison of the total Spt5, the CTR and phospho-CTR profiles with transcription factor 
occupancy profiles could allow identification of CTR- or phospho-CTR-dependent factors. 
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Most importantly, the discovery of a CTR phosphorylation cycle leading to a “CTR code” 
would add a new level of regulation complexity in addition to the CTD code and the histone 
code. In the future it will be most interesting to study the relationship between these three 
different codes and their influence on all transcription related processes. 
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6. Materials and Methods 
6.1. Materials 
6.1.1. Bacterial and yeast strains 
Table 5: E. coli strains 
Strain Description Source 
XL-1 Blue Rec1A;  endA1;  gyrA96;  thi-1; hsdR17; supE44; 
relA1; lac[F’proAB lacIqZΔM15 Tn10(Tetr)] 
Stratagene 
BL21-CodonPlus (DE3)RIL B; F-; ompT; hsdS(rB-, mB-); dcm+;Tetr; gal 
λ(DE3); endA; The [argU, ileY, leuW, Camr] 
Stratagene 
Table 6: S. cerevisiae strains 
Strain Description Source 
BY4741 (wild-type) MATa; his3Δ1 leu2Δ0 met 15Δ0 ura3Δ0 Open Biosystems 
wild-type-pRS316 BY4741; pRS316 [URA3] This study 
Bur1-TAP  BY4741; BUR1::TAP::HIS3MX6 Open Biosystems 
Clp1-TAP BY4741; CLP1::TAP::HIS3MX6 A. Mayer 
Ctk1-TAP  BY4741; CTK1::TAP::HIS3MX6 Open Biosystems 
Elf1-TAP  BY4741; ELF1::TAP::HIS3MX6 Open Biosystems 
Hrp1-TAP BY4741; HRP1::TAP::HIS3MX6 A. Mayer 
Paf1-TAP  BY4741; PAF1::TAP::HIS3MX6 Open Biosystems 
Pap1-TAP BY4741; PAP1::TAP::HIS3MX6 Open Biosystems 
Pcf11-TAP  BY4741; PCF11::TAP::HIS3MX6 Open Biosystems 
Rna14-TAP  BY4741; RNA14::TAP::HIS3MX6 Open Biosystems 
Rna15-TAP  BY4741; RNA15::TAP::HIS3MX6 Open Biosystems 
Rpb3-TAP BY4741; RPB3::TAP::HIS3MX6 Open Biosystems 
Spn1-TAP  BY4741; SPN1::TAP::HIS3MX6 Open Biosystems 
Spt4-TAP  BY4741; SPT4::TAP::HIS3MX6 Open Biosystems 
Spt6-TAP  BY4741; SPT6::TAP::HIS3MX6 Open Biosystems 
Spt16-TAP  BY4741; SPT16::TAP::HIS3MX6 Open Biosystems 
Spt5 ΔCTR BY4741; SPT5Δ931-1063::KANMX6 This study 
Spt5 ΔCTR-pRS316 BY4741; SPT5Δ931-1063::KANMX6; pRS316 
[URA3] 
This study 
Bur1-TAP Spt5 ΔCTR BY4741; BUR1::TAP::HIS3MX6; SPT5Δ931-
1063::KANMX6 
This study 
Clp1-TAP Spt5 ΔCTR BY4741; CLP1::TAP::HIS3MX6; SPT5Δ931-
1063::KANMX6 
This study 
Ctk1-TAP Spt5 ΔCTR BY4741; CTK1::TAP::HIS3MX6; SPT5Δ931-
1063::KANMX6 
This study 
Elf1-TAP Spt5 ΔCTR BY4741; ELF1::TAP::HIS3MX6; SPT5Δ931-
1063::KANMX6 
This study 
6. Materials and Methods 
56 
 
Strain Description Source 
Hrp1-TAP Spt5 ΔCTR BY4741; HRP1::TAP::HIS3MX6; SPT5Δ931-
1063::KANMX6 
This study 
Paf1-TAP Spt5 ΔCTR BY4741; PAF1::TAP::HIS3MX6; SPT5Δ931-
1063::KANMX6 
This study 
Pap1-TAP Spt5 ΔCTR BY4741; PAP1::TAP::HIS3MX6; SPT5Δ931-
1063::KANMX6 
This study 
Pcf11-TAP Spt5 ΔCTR BY4741; PCF11::TAP::HIS3MX6; SPT5Δ931-
1063::KANMX6 
This study 
Rna14-TAP Spt5 ΔCTR BY4741; RNA14::TAP::HIS3MX6; SPT5Δ931-
1063::KANMX6 
This study 
Rna15-TAP Spt5 ΔCTR BY4741; RNA15::TAP::HIS3MX6; SPT5Δ931-
1063::KANMX6 
This study 
Rpb3-TAP Spt5 ΔCTR BY4741; RPB3::TAP::HIS3MX6; SPT5Δ931-
1063::KANMX6 
This study 
Spn1-TAP Spt5 ΔCTR BY4741; SPN1::TAP::HIS3MX6; SPT5Δ931-
1063::KANMX6 
This study 
Spt4-TAP Spt5 ΔCTR BY4741; SPT4::TAP::HIS3MX6; SPT5Δ931-
1063::KANMX6 
This study 
Spt6-TAP Spt5 ΔCTR BY4741; SPT6::TAP::HIS3MX6; SPT5Δ931-
1063::KANMX6 
This study 
Spt16-TAP Spt5 ΔCTR BY4741; SPT16::TAP::HIS3MX6; SPT5Δ931-
1063::KANMX6 
This study 
rna14-1 MATα, ura3-1, trp1-1, ade2-1, leu2-3,112, his3-11,15, 
rna14-1 
(140) 
Y40343 MATα ade2-1 trp1-1 can1-100 leu2-3,112 his3-11,15 
ura3 GAL psi+ tor1-1 fpr1::NAT RPL13A-
2×FKBP12::TRP1 
Euroscarf 
Glc7-FRB-KanMX Y40343; GLC7::FRB::KANMX6 This study 
Ssu72-FRB-KanMX Y40343; SSU72::FRB:: KANMX6 This study 
Ssu72-FRB-Hygromycin Y40343; SSU72::FRB::Hygromycin S. Etzold 
Ssu72-FRB-Hygromycin,  
Glc7-mCherryHis 
Y40343; SSU72::FRB::Hygromycin,  
GLC7::mCherry::HIS3MX6 
This study 
Bur1 as BY4741; BUR1 L149G – FLAG3::KANMX S. Hahn 
Ctk1 as Matα, Δade2::hisG, his3Δ200, leu2Δ0, lys2Δ0, 
met15Δ0, trp1Δ63, ura3Δ0, CTK1 F260G – 
FLAG3::KANMX 
S. Hahn 
Kin28 as Matα, Δade2::hisG, his3Δ200, leu2Δ0, lys2Δ0, 
met15Δ0, trp1Δ63, ura3Δ0, KIN28 L83G 
S. Hahn 
Srb10 as Matα, Δade2::hisG, his3Δ200, leu2Δ0, lys2Δ0, 
met15Δ0, trp1Δ63, ura3Δ0, srb10Δ::KANMX, pSH599 
(ars cen TRP1 srb10as-1 (Y236G)) 
S. Hahn 
ΔBck1 BY4741; BCK1::KANMX Euroscarf 
ΔBdf1 BY4741; BDF1:: KANMX Euroscarf 
ΔFus3 BY4741; FUS3:: KANMX Euroscarf 
ΔKns1 BY4741; KNS1:: KANMX Euroscarf 
ΔKss1 BY4741; KSS1::KANMX Euroscarf 
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Strain Description Source 
ΔMck1 BY4741; MCK1::KANMX Euroscarf 
ΔMpk1 BY4741; MPK1::KANMX Euroscarf 
ΔPbs2 BY4741; PBS2::KANMX Euroscarf 
ΔSnf1 BY4741; SNF1::KANMX Euroscarf 
ΔSwe1 BY4741; SWE1::KANMX Euroscarf 
ΔTpk1 BY4741; TPK1::KANMX Euroscarf 
ΔYak1 BY4741; YAK1::KANMX Euroscarf 
Cdc5-FRB-KanMX Y40343; CDC5::FRB::KANMX6 This study 
Cdk1-FRB-KanMX Y40343; CDK1::FRB::KANMX6 This study 
Hrr25-FRB-KanMX Y40343; HRR25::FRB::KANMX6 This study 
JWY104 MATα pra1-1 prb1-1 prc1-1 cps1-3 ura3Δ5 leu2-3 his- L. Passmore 
6.1.2. Growth media and additives 
Table 7: Growth media 
Growth medium Description Species 
LB 1% (w/v) tryptone; 0.5% (w/v) yeast extract; 0.5% (w/v) NaCl (+ 
1.5% (w/v) agar for selective media plates) 
E. coli 
YPD 2% (w/v) peptone; 2% (w/v) glucose; 1.5% (w/v) yeast extract 
(+1.8% (w/v) agar for solid media plates) 
S. cerevisiae 
SC -ura 0.69% (w/v) yeast nitrogen base; 0.077% (w/v) drop-out -ura; 2% 
(w/v) glucose; (+ 2% (w/v) agar for solid media plates) 
S. cerevisiae 
SC -leu 0.69% (w/v) yeast nitrogen base; 0.069% (w/v) drop-out -leu; 2% 
(w/v) glucose; (+ 2% (w/v) agar for solid media plates) 
S. cerevisiae 
SC -leu + Gal plates 0.69% (w/v) yeast nitrogen base; 0.069% (w/v) drop-out -leu; 2% 
(w/v) galactose; + 2% (w/v) agar for solid media plates 
S. cerevisiae 
 
  
6. Materials and Methods 
58 
 
Table 8: Growth media additives 
Supplement Description Working concentration 
Ampicillin Antibiotic 100 µg/mL 
Chloramphenicol Antibiotic 50 µg/mL 
Hygromycin B Antibiotic 200 µg/mL 
Kanamycin Antibiotic 30 µg/mL 
Tetracycline Antibiotic 12.5 µg/mL 
clonNAT Antibiotic 100 mg/mL 
IPTG Isopropyl-β-D-thiogalactopyranosid 0.5 mM 
Geneticin (G418) Antibiotic 400 µg/mL 
6-Azauracil Pyrimidine analog 50-200 µg/mL 
Mycophenolic acid (MPA) immunosuppressive 15-45 µg/mL 
Rapamycin Immunosuppressant, FKBP12 binding 1 µg/mL 
1-NA-PP1 Kinase inhibitor 5 µM 
1-NM-PP1 Kinase inhibitor 10 µM 
3-MB-PP1 Kinase inhibitor 20 µM 
6.1.3. Plasmids and primers 
Table 9: Plasmids used in this study 
Vector Insert/restriction sites Source 
pFA6a KanMX6 -- (249) 
pFA6a-FRB-KanMX6 FRB-tag Euroscarf 
pFA6a-TAP-KanMX6 (modified) TAPS tag L. Passmore, (250) 
LL280/pYM-TAP TAP-His3 L. Lariviere 
LL592/pFA6a-mCherry mCherry-His3 L. Lariviere 
pRS316 -- (251) 
p415-GAL-S  -- DualSystems Biotech 
p415-GAL-S-Glc7  Glc7 L. Passmore/A. Easter 
p415-GAL-S-Glc7-D94A Glc7-D94A L. Passmore/A. Easter 
p415-GAL-S-Glc7-H247N Glc7-H247N L. Passmore/A. Easter 
pET28b-GST-CTR GST-CTR/NcoI, HindIII This study 
pGEX-4T-1 GST-tag GE Healthcare 
 
  
6. Materials and Methods 
59 
 
Table 10: Cloning primers used in this study 
Primer name Sequence (5’ → 3’) 
KanMX_dCTR fw AGCTGTAAATGCGCATGGAGGCTCAGGTGGTGGCGGTGTCTAAC
GGATCCCCGGGTTAATTAAG 
KanMX_dCTR fw_2 GCAAAACACCAGCTGTAAATGCGCATGGAGGCTCAGGTGGTGGC
GGTGTCTAACGGATCCCCGGGTTAATTAAG 
KanMX_dCTR rev TTGATTTCTTCTTGGGTGATATTGGTTCTCCTTTTGGTGACGCATA
GGCCACTAGTGGATC  
KanMX_dCTR rev_2 GTCTTTTTTATTGATTTCTTCTTGGGTGATATTGGTTCTCCTTTTGG
TGACGCATAGGCCACTAGTGGATC 
KanMX_dCTR rev_3 CACATATGCATACATACATACATACGTATATGTAAAAGTTAGAAT
CAAGGCGCATAGGCCACTAGTGGATC 
dCTR_control_up fw GTGAGGGAGGTGAAGGTA 
dCTR_control_up rev AATTCAACGCGTCTGTGA 
dCTR_control_down fw ATCATGCGTCAATCGTATGT 
dCTR_control_down rev GGAAAGTGGCAGAAAGAAAG 
TAP control rev CTGCAGCGAGGAGCCGTAAT 
Cdc5 AA FRB fw CTTTGATAAAGGAAGGTTTGAAGCAGAAGTCCACAATTGTTACCG
TAGATCGGATCCCCGGGTTAATTAAC 
Cdc5 AA FRB rev CAATGGACTGGTAATTTCGTATTCGTATTTCTTTCTACTTTAATAT
TGGTGAATTCGAGCTCGTTTAAAC 
Cdc5 AA Ctrl  ORF fw GCCGAGTATCTACGTTTGG 
Cdc5 AA Ctrl down rev CTCTAGAACCGCTCAGGC 
Hrr25 AA FRB fw CCACAACAGCCGCCTCAAGATAAACCAGCTGGCCAGTCAATTTG
GTTGCGGATCCCCGGGTTAATTAAC 
Hrr25 AA FRB rev CTATATATACATATGTTTATTTTTGTGCGTTTTGAGCAATATATGT
TGCGAATTCGAGCTCGTTTAAAC 
Hrr25 AA Ctrl  ORF fw CGCAGCCACAACCACAGC 
Hrr25 AA Ctrl down rev GCCAAGAGGTGCTCCGC 
Cdk1 AA FRB fw CCGGATTAGCGCCAGAAGAGCAGCCATCCACCCCTACTTCCAAG
AATCACGGATCCCCGGGTTAATTAAC 
Cdk1 AA FRB rev GACAGTGCAGTAGCATTTGTAATATAATAGCGAAATAGATTATA
ATGCGAATTCGAGCTCGTTTAAAC 
Cdk1 AA Ctrl  ORF fw CTTCAGTGGCGATAGTGAG 
Cdk1 AA Ctrl down rev CGACCTCGGTAAATACGTC 
Glc7 AA-FRB fw new long GAAAGTTTATTATGTTCTTTTCAAATTTTAAAGCCAGCCCAAAAA
AGTCTACCAAGGCAAGCTGGGGGTAGAAAGAAAAAACGGATCCC
CGGGTTAATTAAC 
Glc7 AA FRB rev new GCACTAAAGGGAATTATTTGTGTATATGACGAGTGATGATTGCAT
CTTCCGAATTCGAGCTCGTTTAAAC 
Ssu72 AA FRB-fw GTGGCAAAGCTCACATTCTCAACTACCGTCATTATACGCTCCTTC
ATATTACCGGATCCCCGGGTTAATTAAC 
Ssu72 AA FRB-rev CATGAGGGCCGCTTAATGCTTATGCTTTTCTACAGTAATTGACCG
TTTTGTGAATTCGAGCTCGTTTAAAC 
Glc7 AA Ctrl ORF fw CCCGACGTTGGCTTATTATG 
Ssu72 AA Ctrl ORF fw CGACTTCGTTTTCACTTGTG 
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Primer name Sequence (5’ → 3’) 
KanMX Ctrl rev CTGCAGCGAGGAGCCGTAAT 
FRB Ctrl rev2 CCAGACTCTGAAGGAAACATC 
GFP Hygro fw GATCCGCTAGGGATAACAGGGTAATATCGTACGCTGCAGGTCGA
CGGATCCC 
GFP Hygro rev GGGATCCGTCGACCTGCAGCGTACGATATTACCCTGTTATCCCTA
GCGGATC 
Ssu72 Hygro down rev CATGAGGGCCGCTTAATGCTTATGCTTTTCTACAGTAATTGACCG
TTTTGTATCGATGAATTCGAGCTCG 
Hygro Ctrl fw  GTGGAAACCGACGCCCCAG 
Ssu72 Ctrl down rev CAGTCCTATATCTGGTGATG 
S1Ref2-TAPS GTCCCCATAGTAAAAAGAAATAAATATCCTCCAAGACCAGTACA
C  CTGGAAGTTCTGTTCCAGGGG 
S2Ref2TAPS GAGTATATATACTACATGTTTATGTATCAGCATGTCATAGC 
CATCGATGAATTCGAGCTCG 
Table 11: Readthrough assay and 3’-RACE primers 
Primer name Sequence (5’ → 3’) 
ACT1 (3’-RACE)  
Gene-specific 5’ primer with EcoRI site TATGAATTCTTCTGTTTTGGGTTTGGA 
OligodT anchor primer with XhoI site (229) GACTCGAGTCGACATCGATTTTTTTTTTTTTTTTT 
Anchor primer (229) GACTCGAGTCGACATCGA 
pET28b sequencing primers  
(GATC Biotech AG)  
T7 fw TAATACGACTCACTATAGGG 
pRSET-RP GGGTTATGCTAGTTATTGC 
PMA1 (readthrough transcription) (146)  
Upstream primer  CTATTATTGATGCTTTGAAGACCTCCAG 
Downstream primer 1  CAAGAAAGAAAAAGTACCATCCAGAG 
Downstream primer 2  GTAAATTTGTATACGTTCATGTAAGTG 
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Table 12: qPCR primers used in this study 
Primer name Sequence (5’ → 3’) 
ADH1 5’ fw TTTCCTTCCTTCATTCACGCACA 
ADH1 5’ rev TCAAGTAACTGGAAGGAAGGCCGTA 
ADH1 TSS fw TCCTTGTTTCTTTTTCTGCAC 
ADH1 TSS rev GAGATAGTTGATTGTATGCTTGG 
ADH1 ORF fw AGCCGCTCACATTCCTCAAG 
ADH1 ORF rev ACGGTGATACCAGCACACAAGA 
ADH1 3’ fw CCTGTAGGTCAGGTTGCTTT 
ADH1 3’ rev CGGTAGAGGTGTGGTCAA 
ADH1 polyA fw AAAACGAAAATTCTTATTCTTGA 
ADH1 polyA rev TACCTGAGAAAGCAACCTGA 
ILV5 prom fw ACCCAGTATTTTCCCTTTCC 
ILV5 prom rev TTGTCTATATGTTTTTGTCTTGC 
ILV5 ORF fw CTATCAAGCCATTGTTGACC 
ILV5 ORF rev CTTGAAGACTGGGGAGAAAC 
ILV5 pA fw CCGAAACGCGAATAAATAAT 
ILV5 pA rev GTCCCGATGAGGACTTATACA 
PDC1 prom fw TGCCCCTTTTTCTGTTAGAC 
PDC1 prom rev AATAAGGTGGTGTTGAACGA 
PDC1 ORF fw CAAGACCAAGAACATTGTCG 
PDC1 ORF rev AAAGTGGCGTTTCTGATCTT 
PDC1 pA fw TACCATGGAAAGACCAGACA 
PDC1 pA rev CCCAGACTTAAGCCTAACCA 
PMA1 5’ fw TGACTGATACATCATCCTCTT 
PMA1 5’ rev TTGGCTGATGAGCTGAAACAGAA 
PMA1 ORF fw AAATCTTGGGTGTTATGCCATGT 
PMA1 ORF rev CCAAGTGTCTAGCTTCGCTAACAG  
PMA1 3’ fw GGTTTCTCTGGATGGTACTTT 
PMA1 3’ rev TGACTTGTGTGCGTTTCATA 
TEF1 prom fw ACCACTTCAAAACACCCAAG 
TEF1 prom rev ACGACACCCTAGAGGAAGAA 
TEF1 ORF fw TTGATTATTGCTGGTGGTGT 
TEF1 ORF rev TGTTCTCTGGTTTGACCATC 
TEF1 pA fw ATTTATCCCAGTCCGATTCA 
TEF1 pA rev CTGATGTGATTTCGACCATT 
YER fw TGCGTACAAAAAGTGTCAAGAGATT 
YER rev ATGCGCAAGAAGGTGCCTAT 
All oligonucleotides were purchased from Thermo Fisher Scientific. 
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6.1.4. Antibodies  
Table 13: Antibodies used in this study 
Antibody Stock solution Host Application Source 
Anti-Tubulin 1:1000 rat Western Blot Santa Cruz (sc-69971) 
Anti-GST 1:5000 goat Western Blot GE Healthcare (RPN1236) 
Anti-Spt5 (γN-20) 1:400 goat Western Blot Santa Cruz (sc-26355) 
Peroxidase Anti-
Peroxidase (PAP) 
1:2000 rabbit Western Blot SIGMA (P1291) 
Anti-goat-HRP 1:3000 donkey Western Blot Santa Cruz (sc-2020) 
Anti-mouse-HRP 1:3000 goat Western Blot Bio-Rad (170-6516) 
Anti-rat-HRP 1:5000 goat Western Blot SIGMA (A9037) 
Anti-Rpb3 (1Y26) 1:1000-2000, 
5 µL/IP 
mouse Western Blot, 
ChIP 
NeoClone Biotechnology 
Anti-Tyr1-P (3D12) 1:7, 
100 µL/IP 
rat Western Blot, 
ChIP 
Elisabeth Kremmer/Dirk Eick 
Anti-Ser2-P (3E10) 1:14, 
25 µL/IP 
rat Western Blot, 
ChIP 
Elisabeth Kremmer/Dirk Eick 
Anti-Ser5-P (3E8) 1:14, 
20 µL/IP 
rat Western Blot, 
ChIP 
Elisabeth Kremmer/Dirk Eick 
Anti-Ser7-P (4E12) 1:14, 
50 µL/IP 
rat Western Blot, 
ChIP 
Elisabeth Kremmer/Dirk Eick 
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6.1.5. Buffers and solutions  
Table 14: Buffers and solutions used in this study 
Name Description Application 
100x Protease Inhibitor 0.028 mg/ml Leupeptin, 0.137 mg/ml Pepstatin 
A, 0.017 mg/ml PMSF, 0.33 mg/ml 
Benzamidine in 100% ethanol 
ChIP 
10x PBS 1.37 M  NaCl, 27 mM KCl, 10 mM Na2HPO4, 
20 mM KH2PO4 
adjust pH to 7.4 with HCl, ad 1L H2O, 
autoclave 
e.g. Western Blot, magnetic 
bead ChIP 
10x TBS 1.5 M NaCl, 0.5 M Tris/HCl pH 7.5 ChIP 
1x TAE 4.84 g Tris, 1.14 mL acetic acid, 0.37 g EDTA, 
ad 1 L H2O 
Agarose gel electrophoresis 
1x TBE 89 mM Tris, 89 mM boric acid, 2 mM EDTA Agarose gel electrophoresis 
20x phosphatase 
inhibitor mix 
1 mM NaN3, 1 mM NaF, 0.4 mM Na3VO4 ChIP phosphoisoforms 
5x SDS-PAGE loading 
dye 
250 mM Tris-HCl pH 7.0, 50% (v/v) glycerol, 
0.5% (w/v) bromophenol blue, 7.5% (w/v) 
SDS, 500 mM DTT 
SDS-PAGE 
ChIP elution buffer 
(Sepharose beads) 
50 mM Tris/HCl pH 7.5, 10 mM EDTA, 1% 
SDS 
Sepharose  bead ChIP 
ChIP wash buffer 10 mM Tris/HCl pH 8.0, 0.25 M LiCl, 0.5% 
NP40, 0.5% Sodium deoxycholate, 1 mM 
EDTA 
Sepharose  bead ChIP 
Coomassie staining 
solution 
50% (v/v) ethanol, 7% (v/v) acetic acid, 
0.125% (w/v) Coomassie Brilliant Blue R-250 
SDS-PAGE 
CPF buffer A 20 mM HEPES pH 7.9, 150 mM KCl, 0.5 mM 
Mg(OAc)2, 3 mM DTT, 0.2 mM PMSF, 0.2 
mM benzamidine-HCl 
CPF purification 
CPF buffer B 20 mM HEPES pH 7.9, 400 mM KCl, 0.5 mM 
Mg(OAc)2, 3 mM DTT, 0.2 mM PMSF, 0.2 
mM benzamidine-HCl 
CPF purification 
CPF buffer C 20 mM HEPES pH 7.9, 150 mM KCl, 0.5 mM 
Mg(OAc)2, 3 mM DTT 
CPF purification, phosphatase 
assay 
CPF lysis buffer 100 mM HEPES pH 7.9, 200 mM KCl, 0.5 mM 
MgCl2, 0.5 mM Mg(OAc)2, 10% glycerol 
CPF purification 
Destaining solution 5% (v/v) ethanol, 7.5% (v/v) acetic acid SDS-PAGE 
FA-lysis buffer (150) 150 mM NaCl, 50 mM HEPES, pH 7.5 with 
KOH, 1 mM EDTA, 1% Triton X-100, 0.1% 
Sodium deoxycholate, 0.1 % SDS 
ChIP 
FA-lysis buffer (500) 500 mM NaCl, 50 mM HEPES, pH 7.5 with 
KOH, 1 mM EDTA, 1% Triton X-100, 0.1% 
Sodium deoxycholate, 0.1 % SDS 
Sepharose  bead ChIP 
HU buffer 5% (w/v) SDS, 0.2 M Tris/HCl pH 6.8, 10 mM 
EDTA, 215 mM β-mercaptoethanol,  8 M urea, 
0.01% (w/v) bromophenolblue 
Western Blot 
IP elution buffer 
(magnetic beads) 
1% SDS, 0.1 M NaHCO3 Magnetic bead ChIP 
6. Materials and Methods 
64 
 
Name Description Application 
LiCl wash buffer 100 mM Tris-HCl pH 7.5, 500 mM LiCl, 1% 
NP40, 1% sodiumdeoxycholat 
Magnetic bead ChIP 
LitPEG 40% (w/v) PEG 3350,  in TELit pH 8.0, filter 
sterilized 
Chemical transformation of 
yeast 
LitSorb 18.2% (w/v) D-Sorbitol, in TELit, pH 8.0 Chemical transformation of 
yeast 
Pulldown lysis buffer 50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1 mM 
DTT 
GST-pulldown 
RNase storage buffer 10 mM HEPES pH 7.5, 20 mM NaCl, 0.1% 
Triton X-100, 1 mM EDTA and 50% (v/v) 
glycerol  
RNase ChIP 
SDS-PAGE running 
buffer  
invitrogen SDS-PAGE 
Ssu72 buffer 50 mM Tris-HCl pH 8.0, 10 mM MgCl2, 20 
mM KCl, 2% glycerol, 5 mM DTT, 0.1 mM 
EDTA, 0.025% Tween 20 
Dephosphorylation assay 
TE buffer 10 mM Tris-HCl pH 7.5, 1 mM EDTA ChIP 
TELit, pH 8.0 155 mM LiOAc, 10 mM Tris/HCl, pH 8.0, 1 
mM EDTA, pH 8.0 
Chemical transformation of 
yeast 
TFB-I 30 mM KOAc, 50 mM MnCl2, 100 mM RbCl, 
10 mM CaCl2, 15% glycerol 
Preparation of chemically 
competent E. coli cells 
TFB-II 10 mM MOPS pH 7.0, 75 mM CaCl2, 10 mM 
RbCl, 15% glycerol 
Preparation of chemically 
competent E. coli cells 
Western transfer buffer invitrogen Western Blot 
Yeast lysis buffer 50 mM Tris-HCl pH 7.5, 10 mM EDTA, 5.15 
µM β-mercaptoethanol 
Yeast genomic DNA isolation 
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6.2. Methods 
6.2.1. Molecular cloning methods 
Polymerase chain reaction (PCR) 
DNA fragments for homologous recombination were amplified using the Phusion High-
Fidelity DNA Polymerase (Finnzymes), 25-100 ng of template, 0.4 µM primers, 0.2 mM 
dNTPs and 35 cycles of a 3-step PCR reaction: 98°C for 7 sec, 50-60°C for 20 sec, 72°C for 
1-3 min. Colony PCRs were performed using Taq polymerase (Fermentas), 3-5 µL of crude 
cell lysate, 0.25 µM primers, 2 mM MgCl2, 0.1 mM dNTPs, and 35 cycles of a 3-step PCR 
reaction: 94°C for 1 min, 50-60°C for 30 sec, 72°C for 30 sec. Annealing temperatures and 
elongation times were optimized for specific primer pairs. 
Restriction and ligation 
Restriction digest was performed with appropriate restriction enzymes and the conditions 
defined by NEB double digest finder. Restricted plasmids and inserts were ligated in a volume 
ratio of 2:5 using T4 DNA ligase (Fermentas) at 16-20°C overnight. 
Agarose gel electrophoresis 
1-2% agarose, SybrSafe (Invitrogen, 1x) in 1x TAE or TBE buffer were covered with 1x TAE 
or TBE buffer. PCR samples (50 µL) were mixed with 6x DNA sample buffer (10 µL) and 
loaded on the gel. A voltage of 120-150 V was applied for approximately 45 min to separate 
DNA fragments according to their size. DNA bands were visualized by UV-illumination. If 
necessary, resulting bands of the PCR products were excised under UV light. Gel slices were 
processed with the QIAquick Gel Extraction Kit according to the manufacturer’s instruction 
except for elution in 30 µL of water. 
6.2.2. Bacterial methods 
Competent cells 
For electroporation, E. coli cells from a preculture were grown at 37°C and 160 rpm to an 
OD600 of 0.4-0.6. Cells were cooled on ice for 15 min, harvested, for electroporation washed 
twice with ice-cold sterile Millipore water, resuspended in 10% glycerol, for chemical 
transformation washed with TFB-I, resuspended in 2 mL TFB-II per 100 mL culture, in both 
cases flash-frozen and stored at -80°C. 
Plasmid Minipreparation 
Single colonies were picked, transferred to 5 mL LB media containing respective antibiotics 
and incubated on the shaker at 37°C for 18 h. Next, cells were harvested and to extract the 
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plasmid DNA from the cells, the QiaPrep Spin MiniPrep Kit (QIAGEN) was applied 
according to the manufacturer’s instructions but eluting in water.  
Transformation 
A 50 µL aliquot of competent E. coli cells was transformed with 0.5 µL of purified plasmid 
DNA or 5 µL of ligation product. Chemically competent cells with DNA were kept on ice for 
10 min, heat-shocked at 42 °C for 45 sec and after another 2 min on ice resuspended in  
700 µL of prewarmed LB media and incubated on the shaker at 37°C and 650 rpm for 30 min. 
Finally, cells were transferred to LB plates containing respective antibiotics and incubated at 
37°C for 16 h. Electrocompetent cells were transformed with DNA by pulsing 2.5 kV for  
5 msec with the MicroPulserTM Electroporator (BioRad) and incubation on ice for 5-10 min. 
Prewarmed LB was added and cells processed as above. 
6.2.3. Yeast methods 
Chemical transformation of yeast cells 
A 50 mL yeast culture in YPD was grown from a preculture to an OD600 of 0.5-0.7. Cells 
were harvested at 4,000 rpm for 10 min at room temperature, washed with 25 mL sterile 
water, then with 5 mL LitSorb, then resuspended in 360 µL LitSorb. Salmon sperm DNA 
(Sigma) was heated for 10 min at 100°C and cooled on ice. 40 µL of DNA were added to the 
cells. 10 µL of PCR product or 1 µL of purified plasmid were added to a 50 µL aliquot of 
competent cells and diluted with 360 µL of LitPEG. After incubation for 30 min at room 
temperature, 47 µL of DMSO were added and cells incubated again for 15 min at 42°C. 
Finally, cells were centrifuged for 3 min at 2,000 rpm and the pellet resuspended in 1 mL of 
YPD and incubated for 3 h on a turning wheel at room temperature. Cells were centrifuged 
again, resuspended in 200 µL of YPD, plated on G418-plates and incubated at 30°C for  
3 days. 
Transformation of yeast by electroporation 
A 50 mL yeast culture in YPD was grown from a preculture to an OD600 of 0.7-0.8. Cells 
were harvested by centrifugation at 4,000 rpm and 4°C, washed twice with 50 mL ice-cold 
sterile water and once with 50 mL ice-cold 1 M sorbitol. Next, the pellet was resuspended in 
20 mL of 0.1 M LiOAc/30 mM DTT and incubated for 30 min at 160 rpm and 30°C. Cells 
were harvested and the pellet washed twice with 50 mL ice-cold 1 M sorbitol and finally 
resuspended in 100 µL of 1 M sorbitol. For transformation, 5 µL of DNA solution (at least  
1 µg in total) were added to 100 µL of cell suspension and a pulse of 1.5 kV (5 msec) was 
applied to the cells in an electroporation cuvette in a MicroPulserTM Electroporator (Bio-Rad). 
1 mL of prewarmed YPD media was added and the cell suspension incubated at 30°C and  
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700 rpm for 3-4 h. Cells were pelleted at 2,000 rpm for 3 min, resuspended in 200 µL of 
media, and plated on corresponding marker plates and incubated at 30°C for 2-3 days. 
Strain cloning and validation 
S. cerevisiae kinase deletion strains were validated by colony PCR using a gene-specific 
upstream primer and a reverse primer within the KanMX cassette. S. cerevisiae strains Cdc5-, 
Cdk1-, Glc7-, Hrr25- and Ssu72-FRB-KanMX6 were cloned by amplifying the cassette from 
vector pFA6a-FRB-KanMX6 (Euroscarf) with suggested primer pairs F2, R1 (252) and 
transforming the parental strain Y40343 by homologous recombination. The functional 
insertion of the FRB tag was verified (i) by PCR and (ii) by spot diluting the strains on YPD + 
rapamycin plates (Figure 10 and Figure 17). The mCherry-tag on Glc7 was inserted by 
homologous recombination of a PCR product amplified from the plasmid pFA6a-mCherry-
His3MX6. For recovery experiments, the Glc7-FRB strain was transformed with the plasmids 
p415-GAL-S as a control or the same plasmid expressing galactose-inducible wild-type, 
D94A or H247N catalytic mutants of Glc7.   
S. cerevisiae strains containing C-terminally TAP tagged target proteins (TAP strains) were 
validated (i) by colony PCR using a gene-specific upstream primer and a reverse primer 
within the TAP tag and (ii) by Western blotting with an anti‐TAP antibody (PAP, Sigma) to 
control the expression level of TAP-tagged proteins. The 15 C-terminal hexapeptide repeats, 
amino acids 931 to 1063, of Spt5 were deleted from TAP strains by homologous 
recombination with the KanMX6 cassette, amplified from the pFA6a-KanMX6 vector.  
Yeast genomic DNA 
Yeast cells from 1 mL overnight culture diluted to an OD600 of 5.0 were harvested and 
resuspended in 180 µL of yeast lysis buffer containing 1.8 units of lyticase (Sigma). Genomic 
DNA was isolated using the QIAcube (QIAGEN) and the standard protocol “DNeasy Blood 
& Tissue - Bacteria (Gram+) or yeast - Enzymatic lysis” according to the manufacturer’s 
instructions. The yield of DNA was 50-150 ng/µL. 
Colony PCR 
A single colony from the original transformation plate was transferred to a second plate. A 
pinhead-sized amount of cells was picked from this replated single colony and dissolved in 
100 µL of 20 mM NaOH. Approximately 50 µL of 0.5 mm glass beads (Roth) were added to 
the solution which was boiled at 95°C and 1,400 rpm in a thermomixer for 5 min. Afterwards 
the sample was centrifuged at 13,000 rpm for 1 min. 5 µL of the supernatant was used as 
template for a standard PCR reaction as described in chapter 6.2.1. 
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Phenotyping 
For growth curve measurements, liquid overnight cultures of wild-type and mutant yeast 
strains were diluted with YPD to a starting OD600 of 0.1. Yeast cells were grown for 18 h and 
the OD600 was determined every 90 min. Biological triplicate measurements were performed.  
For spot dilutions in general, yeast strains were grown in YPD or Synthetic Complete (SC) 
media at 30°C to stationary phase and diluted to an OD600 of ~1.0 with water. 3 µL of cells 
were spotted on corresponding plates in 10-fold serial dilutions manually or using the 
epMotion 5075 (Eppendorf). Plates were incubated at 30°C and inspected daily.  
For Figure 10 and Figure 17a, FRB strains were grown in YPD and spotted on YPD plates 
with or without 1µg/mL f.c. rapamycin (LC Laboratories). For Figure 18a, the Glc7-FRB 
strain containing p415-GAL-S plasmids was grown in SC -leu media with 2% glucose, 
resuspended in SC -leu media without glucose and spotted on SC -leu plates with 2% glucose 
(repressed) or galactose (induced) with or without 1 µg/mL rapamycin. For Figure 20a, wild-
type and ΔCTR cells transformed with the pRS316 plasmid were grown in SC -ura media and 
spotted on SC -ura plates containing 50 µg/ml of 6-AU or 15 µg/ml of mycophenolic acid 
(MPA). 
Fluorescence microscopy 
For fluorescence microscopy, cells were grown in 1 mL YPD + 40 µg/mL adenine 
hemisulfate (Sigma) to an OD600 of ~0.8 and 0.5 mL of paraformaldehyde solution  
(10% paraformaldehyde (Sigma), 13 mM NaOH, 150 mM PBS) was added for 10 min. Cells 
were washed with 1x PBS once, resuspended in 50 µL 1x PBS and applied to a poly-L-lysine-
coated glass slide (Sigma, Roth). Remaining liquid was removed and 1.0 ng/µL DAPI 
(Sigma) in 1x PBS was applied for 1 min. Fixed cells on glass slide were washed twice with 
1x PBS and covered with a cover slip. DAPI and mCherry fluorescence was analyzed under 
the microscope (Leica DM2500, EL 6000). Camera DFC365FX and Software LAS AF 6000 
Modular Systems Version 2.6.0.7266 (Leica) were used for image analysis.  
Yeast cell lysates 
Yeast cultures were grown in 200 ml YPD medium at 30°C to an OD600 of ~ 0.8. Subsequent 
steps were performed at 4°C. Cells were collected by centrifugation, washed with 1x TBS and 
FA lysis buffer containing protease inhibitor (PI). Cell pellets were flash-frozen in liquid 
nitrogen and stored at -80°C. Pellets were thawed, resuspended in 1 ml FA lysis buffer 
containing PI and disrupted by bead beating (Retsch) in the presence of 1 ml silica-zirconia 
beads for 30 min at 4°C. Lysis efficiency was typically >80%. Cell debris was removed by 
centrifugation. 
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Denatured yeast cell lysates 
A pinhead-sized amount of cells from a YPD plate was resuspended in 1 mL of cold water. 
150 µL of 7.5% β-Mercaptoethanol in 1.85 M NaOH were added and cells were incubated for 
15 min on ice. Afterwards, 150 µL of 55% TCA were added and the sample incubated for  
10 min on ice. Next, cells were centrifuged for 10 min at 14,000 rpm and 4°C, the supernatant 
discarded and the pellet resuspended in 50 µL HU buffer. The sample was neutralized using 
5-15 µL of 1 M Tris base and incubated for 10 min at 1,400 rpm and 65°C. Cells were 
centrifuged for 5 min at 14,000 rpm at room temperature and the supernatant was collected. 
Absorption of samples at 280 nm wavelength was determined at a BioPhotometer 
(Eppendorf) using UV cuvettes and a 1:20 dilution of the lysates in water. 
6.2.4. Protein methods 
GST protein expression and -pulldown 
A synthetic DNA construct of the GST tag based on the pGEX3T vector fused to the DNA 
sequence coding for Spt5 CTR residues 931-1063 was synthesized (MrGene GmbH) and 
cloned into vector pET28b. Expression of the GST-Spt5CTR fusion construct (pET28b) and 
the GST tag alone (pGEX-4T-1) in E. coli was induced with 0.5 mM IPTG at 18 °C overnight 
in 1 L cultures. Cells were lysed by sonification in 50 mL pulldown lysis buffer with PI for  
15 min (Branson Sonifier 250). The cell debris was removed by centrifugation. For pulldown 
experiments, E. coli cell lysates were incubated with 100 µL Glutathione Sepharose beads 
(GE Healthcare) and pre-equilibrated in pulldown lysis buffer for 1 h at 4°C. Beads were 
washed eight times with pulldown lysis buffer and incubated with 300 µL lysate from yeast 
strains expressing TAP-tagged versions of CFI subunits for 1 h at room temperature. Next, 
beads were washed eight times with pulldown lysis buffer and proteins were eluted from the 
beads eight times with pulldown lysis buffer containing 10 mM glutathione. All elution 
fractions were pooled and the protein precipitated with 10% TCA. The protein pellet was 
washed with ice-cold acetone and resuspended in 2x SDS-PAGE loading dye. Wash and 
elution fractions were analyzed by SDS-PAGE and Western blotting with antibodies against 
the TAP-tag of CFI subunits and the GST-tag.  
CPF purification 
Primers specific to 40-bp of the C-terminus and 3’-UTR of REF2 were used to PCR amplify 
the TAP tag cassette from a modified pFA6a-TAP-kanMX6 vector (250), where a StrepII tag 
replaces the calmodulin binding peptide. The PCR product was transformed into S. cerevisiae 
strain JWY104 via homologous recombination. Cells were grown at 30°C in YPD to an OD600 
of 5.0-5.5, pelleted at 6,700 g, washed once with cold water, pelleted at 3,200 g, flash-frozen 
in liquid nitrogen and stored at -80 °C. Cells were mixed 1:1 (v:v) with CPF lysis buffer 
containing 1.6 µg/mL DNAse I and EDTA-free protease inhibitor cocktails tablets (Roche) 
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and lysed at 35 kPsi via cell disruption (Constant Systems). Lysate was clarified at 25,000 g 
for 25 min, bound to IgG sepharose (GE Healthcare) for 1 h and washed with CPF buffer A. 
CPF was eluted from the IgG resin with TEV protease at 16 °C for 1.5 h, and the supernatant 
applied to StrepTactin sepharose (GE Healthcare) for 1 h. StrepTactin resin was washed three 
times with CPF buffer B, three times with CPF buffer C, then eluted with 5 mM desthiobiotin 
in buffer C. Concentration was determined via absorbance at 280 nm using a calculated 
extinction coefficient. Bands were excised from Coomassie blue-stained SDS-PAGE gels 
(Figure 13a) and identified via tryptic digest mass spectrometry by the Passmore laboratory. 
SDS-PAGE 
Protein samples were separated by SDS-PAGE according to their size using NuPAGE 4-12% 
Bis-Tris gels (life technologies) in the novex Mini-cell chambers (Invitrogen) and MES and 
MOPS buffers according to the manufacturer’s instructions. Protein samples were boiled in  
5x SDS loading dye for 1.5-5 min before loading. PAGE was performed at 160-200 V. Gels 
were stained using Coomassie staining solution or Instant BlueTM (expedeon) for 20 min and 
destaining overnight or used for Western Blot.  
Western Blot  
After SDS-PAGE using PageRuler™ Prestained Protein Ladder (Fermentas), the gel was 
blotted for 1-2 h at 100-150 V or overnight at 30 V in a Mini Trans-Blot System (Bio-Rad) 
filled with NuPAGE® transfer buffer containing 10% (v/v) ethanol at 4°C onto a 
polyvinylidene difluoride (PVDF) membrane (Roth), which had been pre-soaked in ethanol 
and transfer buffer. The membrane was blocked with 2% milk powder (Roth) in 1x PBS for 
20 min or overnight, then probed with primary antibodies or HRP-coupled PAP antibody for 
TAP tag detection in 2% milk/PBS using the appropriate dilution (Table 13). Afterwards, 
membranes were washed three times for 5 min with 2% milk/PBS and incubated for 1 h with 
secondary antibodies in 2% milk/PBS using the appropriate dilution. Finally, membranes 
were washed three times with 1x PBS for 5 min. Antibody detection was performed using the 
Pierce® ECL Western Blotting Substrate (Thermo Scientific) and Amersham HyperfilmsTM 
ECL (GE Healthcare) and developing with X-omat M35 (Kodak) or using the LAS-3000 
camera (FUJIFILM). For Figure 20c, protein signals were quantified relative to α-tubulin 
signals as loading control using the ImageQuant 5.0 software (GE Healthcare).  
Dephosphorylation assay with RNA Pol II and CPF 
After prephosphorylation with MAP Kinase (NEB) for 60 min at 30°C, with the kinase 
inactivated for 20 min at 65°C, 234 nM of purified Pol II (253) was incubated with 59 nM of 
CPF at 30°C for indicated periods in CPF buffer C. The CPF complex was purified and 
analyzed by Lori Passmore’s group in Cambridge as described above. For Glc7 inhibition,  
10 mM EDTA or 200 nM mycrocystin-LR (Sigma) was added. Samples were dissolved in  
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3x SDS-PAGE buffer and boiled at 95°C for 90 sec. After SDS-PAGE (0.5 µg of Pol II per 
lane), samples were blotted onto a PVDF membrane (Millipore) and the membrane probed 
with primary antibodies α-Tyr1P, α-Ser5P, α-Ser2P and α-Rpb3. Secondary antibodies α-rat 
IgG HRP and α-mouse IgG HRP were used. Antibody detection by Western blotting was 
performed as described above. 
For Pol II dephosphorylation with human Ssu72 (hSsu72), 3 µg of Pol II was incubated with 
1, 3 or 5 µg purified recombinant hSsu72 (204) in Ssu72 buffer for 2 h at 30°C. Samples were 
dissolved in 3x SDS-PAGE buffer and processed as described above.  
6.2.5. RNA methods 
RNA isolation 
For RNA isolation, overnight yeast cultures were diluted in 20 mL fresh YPD medium to an 
OD600 of ~ 0.1 and grown at 30°C to mid-log phase (OD600 ~ 0.8). The RiboPure™-Yeast Kit 
(Applied Biosystems) was used to isolate yeast RNA according to the manufacturer’s 
instructions. 
3’-RACE 
3’-RACE was performed for the ACT1 gene as described (229). This gene was shown to 
possess several alternative pA sites and was used in 3’-end processing studies (146, 228). The 
ACT1 cDNA was synthesized as described (146) using Superscript II reverse transcriptase 
(Invitrogen), 0.5 µM oligodT-anchor primer containing a XhoI restriction site, and 2 µg RNA 
template. Next, RNA was digested using RNase H (New England BioLabs Inc.) for 20 min at 
37°C. The enzyme was inactivated at 65°C for 20 min. PCR reactions were conducted using 
the cDNA samples, 0.25 µM gene-specific upstream primer containing an EcoRI restriction 
site, an anchor primer and Taq DNA Polymerase (Fermentas). PCR product and the pET28b 
vector were digested with EcoRI-HFTM as well as XhoI (New England BioLabs Inc.), ligated 
and transformed into competent E. coli XL1-blue cells. Plasmids from 25 E. coli colonies 
from each strain were sequenced (GATC Biotech) using pET28b sequencing primers.  
Readthrough assay 
The readthrough was performed for the PMA1 gene according to (146), using a gene-specific 
forward primer and two reverse primers positioned at different regions downstream of the 
transcription termination site (Figure 28). RNA isolation, reverse transcription and PCR were 
conducted as described above and the PCR products for wild-type and Spt5 ΔCTR mutant 
were compared by standard agarose gelelectrophoresis. RNA isolation from the rna14-1 
temperature sensitive mutant was performed as described before, but with the following 
modifications. Yeast cultures were either grown at 24°C to mid-log phase before RNA 
isolation (rna14-1 24°C, Figure 28b) or were grown to an OD600 of ~ 0.8 at 24°C and then 
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transferred to 37°C (restrictive temperature) for 1 h (rna14-1 37°C, Figure 28b) before RNA 
was isolated. 
6.2.6. ChIP methods 
General ChIP with protein-specific antibodies 
For ChIP experiments, yeast cultures were grown in 40 ml YPD medium at 30°C to mid-log 
phase (OD600 ~ 0.8) in biological duplicates, treated with 1% formaldehyde (Sigma) for  
20 min at 20°C, and crosslinking was quenched with 5 ml 3 M glycine for 10 min. For Shokat 
strains or anchor-away strains, twice the volume of culture was grown and then splitted at an 
OD600 of 0.65. Both new cultures were incubated with equal volumes of kinase inhibitor and 
DMSO, respectively, for Shokat strains or rapamycin (1µg/mL f.c. in DMSO) and DMSO, 
respectively, for anchor-away strains at 30°C for another 60 min before formaldehyde 
crosslinking. Subsequent steps were performed at 4°C with pre-cooled buffers containing PI. 
Cells were collected by centrifugation, washed with 1x TBS, and twice with FA lysis buffer. 
Cell pellets were flash-frozen in liquid nitrogen and stored at -80°C. Pellets were thawed, 
resuspended in 1 ml FA lysis buffer, which contained 1x phosphatase inhibitor mix (Table 14) 
or a phosphatase inhibitor cocktail (PhosSTOP, Roche) when CTD phosphoisoform 
antibodies were used (Table 13), and disrupted by bead beating (Retsch) in the presence of  
1 ml silica-zirconia beads for 30 min at 4°C. Lysis efficiency was typically >80%. Chromatin 
was solubilized and fragmented via sonication with a BioruptorTM UCD-200 (Diagenode 
Inc.) connected to a water cooler system for 35 cycles 30 sec on/30 sec off at high intensity. 
After putting aside 30 µL chromatin solution as Input sample, immunoprecipitation was 
performed either using sepharose or magnetic beads. For the sepharose bead protocol, 670 µl 
of sample was immunoprecipitated with the appropriate amount of antibody per 
immunoprecipitation (IP) (Table 13) at 4°C overnight on a rotating wheel. 12.5 µL Protein G 
Sepharose 4 Fast Flow and 12.5 µL nProtein A Sepharose 4 Fast Flow (GE Healthcare) were 
then coupled to the antibodies in the chromatin solution for 90 min at 4°C on a rotating wheel. 
Immunoprecipitated chromatin on sepharose beads was washed in Ultrafree® Centrifugal 
Filters (Durapore PVDF 5.0 µm) three times with 380 µL FA lysis buffer, twice with FA lysis 
buffer containing 500 mM NaCl, twice with ChIP wash buffer and once with TE buffer. 
Proteins and DNA were eluted from the beads for 10 min at 65 °C with 120 µL ChIP elution 
buffer. Eluted chromatin was digested with Proteinase K (Sigma) at 37°C for 2 h and the 
reversal of crosslinks was performed at 65°C overnight. DNA was purified with the QIAquick 
PCR Purification Kit (Qiagen) according to the manufacturer’s instructions. For the magnetic 
bead protocol, 670 µL of chromatin sample was incubated with 16.5 µL antibody-coated and 
prewashed magnetic Dynabeads® Protein G (life technologies) at 4°C overnight. Beads were 
prewashed four times with 5 mg/mL BSA in 1x PBS with PI, coated with the respective 
antibody for 30 min at 4°C and washed again three times. After immunoprecipitation, beads 
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were washed five times with LiCl wash buffer and once with TE buffer. Immunoprecipitated 
chromatin was eluted for 5 min at 95°C with IP elution buffer.  
ChIP of TAP-tagged proteins 
ChIP of TAP-tagged proteins was performed as described above with the following 
modifications: For the IP, 670 µl of TAP-tagged sample was immunoprecipitated with 25 µl 
IgG Sepharose 6 Fast Flow (GE Healthcare) at 4°C for 1 h.  
RNase ChIP 
The RNase-ChIP assay was performed as described above with the following adaptations: 
First, the crosslinking time was reduced to 5 min. Second, chromatin solution was divided 
into two samples before the IP step. One chromatin sample was treated with 7.5 U of  
RNase A and 300 U of RNase T1 (Ambion), the other sample was treated with the same 
volume of RNase storage buffer. After incubating for 30 min at room temperature, the IP was 
performed as above. The RNase ChIP data of Rna14 and Rna15 was further analyzed as 
follows: After averaging fold enrichments of the respective gene region between biological 
replicates, the values of the chromatin samples that were not treated with the RNase mix were 
set to 100% and all other values multiplied by the same factor.  
Fragment size control 
Chromatin fragment size was determined after DNA shearing by phenol‐extracting a 100 µL 
sample twice and ethanol‐precipitating over‐night. The pellet was resuspended in 20 µl TE 
buffer and incubated with 10 µl RNase A/T1 Mix (2 mg/ml RNase A, 5000 U/ml RNase T1; 
Fermentas) at 37°C for 1 h. Alternatively, the chromatin sample was diluted with 92 µL TE 
buffer and 8 µL Proteinase K (Sigma) were added at 65°C overnight. RNase A/T1 Mix digest 
was performed at 37°C for 30 min. The resulting DNA sample was in both cases analyzed on 
a 1.5% agarose gel. 
Quantitative real-time PCR (qPCR) 
Input and immunoprecipitated samples were assayed by qPCR to assess the extent of protein 
occupancy at different genomic regions. Primer pairs directed against 60-70 nucleotide long 
regions of the transcriptional start site (TSS, 5’), coding (ORF), pA and 3’ regions of the 
ADH1, ILV5, PDC1, PMA1 and TEF1 genes as well as against a heterochromatic control 
region of chromosome V were used to determine PCR efficiencies. All PCR efficiencies 
ranged between 95-100%. PCR reactions contained 1 µl DNA template, 2 µl of 10 µM primer 
pairs and 12.5 µl iTaq SYBR Green Supermix (Bio-Rad). qPCR was performed on a Bio-Rad 
CFX96 Real-Time System (Bio-Rad Laboratories, Inc.) using a 3 min denaturing step at 
95°C, followed by 49 cycles of 30 sec at 95°C, 30 sec at 61°C and 15 sec at 72°C. Threshold 
cycle values were determined by application of the corresponding Bio-Rad CFX Manager 
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software versions 1.1 and 3.0 using the Ct determination mode “Regression”. Fold enrichment 
of any given region over an ORF-free heterochromatic region on chromosome V (control) 
was determined as described (254) using Microsoft Excel 2007 and the following formula:  
ܨ݋݈݀	݁݊ݎ݄݅ܿ݉݁݊ݐ ൌ 1.9
େ୲౅ౌ,ౙ౥౤౪౨౥ౢି	େ୲౅౤౦,ౙ౥౤౪౨౥ౢ
େ୲౅ౌିେ୲౅౤౦  
For chapter 2.3, Tyr1-P fold enrichments were normalized against Rpb3 fold enrichments 
using median-centered normalization: Tyr1-P values for every sample (e.g. replicate 1 and 2 
of untreated or wild-type) and every primer pair were divided by the median of all 
corresponding Rpb3 values (median of replicate 1 and 2 of untreated or wild-type) and 
multiplied by the overall median of all Rpb3 values (median of untreated or wild-type 1 and 2 
+ treated or mutant 1 and 2). Resulting relative fold enrichments were averaged. 
6.2.7. ChIP and tiling microarray hybridization (ChIP-chip) 
ChIP for ChIP-chip 
ChIP was performed in duplicates like described above with the following modifications:  
(i) yeast cultures were grown in 600 mL YPD to an OD600 of ~0.8, or in 1.2 L when split 
afterwards; (ii) cell disruption by bead beating was performed either using the Retsch mill for 
2 h with 5 min breaks on ice after 45 and 90 min or using the FastPrep®-24 Instrument (MP 
Biomedicals) with the QuickPrep adaptor 8 times for 40 sec at 4.0 m/s; (iii) the chromatin 
pellet was washed twice with FA lysis buffer by resuspending and centrifuging for 15 min at 
13,000 rpm; (iv) when sepharose beads were used, the elution from the beads was done for  
60 min at 65°C; (v) three parallel IPs were performed from each 600 mL culture and the DNA 
was combined before purification with the QIAquick PCR Purification Kit (Qiagen) 
according to the manufacturer’s instructions with an elution volume of 100 µL. 
RNase digest and whole genome amplification 
IP and input samples were digested with 5 µg RNase A for 20 min at 37°C, then a second  
PCR purification step was performed in which the three identical IPs were combined via 
purification in one column and elution in 50 µL. IP samples were concentrated using the 
Concentrator plus (Eppendorf) to 10 µL volume. IP and input samples were amplified with 
the GenomePlex© Complete Whole Genome Amplification 2 (WGA2) Kit (Sigma) and the 
WGA Protocol for ChIP‐chip from the Farnham Lab (http://www.genomecenter.ucdavis.edu/ 
farnham/protocol.html): Firstly, a library preparation step was performed to anneal uniform 
priming sites to the DNA fragments. 20 ng of Input DNA in 10 µL and the 10 µL 
concentrated IP DNA were incubated with 2 µL Library Preparation buffer and 1 µL 
Stabilization Solution in thin-walled 0.2 mL tubes for 2 min at 95°C, then cooled for 2 min.  
1 µL Library Preparation Enzyme was added and the mixture incubated in a thermocycler as 
follows: 16°C for 20 min, 24°C for 20 min, 37°C for 20 min and 75°C for 5 min. Secondly, 
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the first amplification round was performed with 7.5 µL 10x Amplification Master Mix and  
5 µL WGA DNA Polymerase in 75 µL volume using the following program: 95°C for 3 min, 
then 14 cycles of 94°C for 15 sec and 65°C for 5 min. DNA was purified using the PCR 
Purification Kit (Qiagen) and concentration was determined with a ND‐1000 Spectro-
photometer (NanoDrop Technologies). Thirdly, a second amplification round was performed 
with 20 ng of the resulting DNA using the same reaction but adding 0.4 mM dUTPs 
(Promega) to be incorporated for enzymatic digestion. DNA was purified and concentration 
determined as above.  
Enzymatic DNA fragmentation, labeling and microarray hybridization 
These steps were performed according to the Affymetrix Chromatin Immunoprecipitation 
Assay Protocol P/N 702238 using the GeneChip® WT Double‐Stranded DNA Terminal 
Labeling Kit (P/N 900812, Affymetrix). Enzymatic fragmentation and terminal labeling were 
performed by application of the GeneChip® WT Double‐Stranded DNA Terminal Labeling 
Kit (P/N 900812, Affymetrix): 5.5 µg of re-amplified DNA was fragmented in a 48 µL 
reaction containing fragmentation buffer, 15 U UDG and 225 U APE1 at 37°C for 1 h 15 min 
and inactivation at 93°C for 2 min. Fragment size was determined on Invitrogen E-Gels (4%) 
and was usually around 50‐70 bp. Fragments were labeled at the 3’‐end in a 60 µL reaction 
with 1 µL of 5 mM GeneChIP® DNA labeling reagent and 60 U terminal nucleotidyl 
transferase (TdT) at 37°C for 1 h and inactivation at 70°C for 10 min. For the following steps, 
the GeneChip® Hybridization, Wash, and Stain Kit (P/N 900720) was used: The complete 
labeled DNA sample was applied to  a high‐density custom‐made GeneChip® S. cerevisiae 
tiling array (11) (Affymetrix, P/N 520055) in a 200 µL volume containing 50 pM of control 
Oligonucleotide B2, 1x Hybridization mix and 7% DMSO in nuclease-free water and 
hybridized at 45°C for 16 h by rotation at 60 rpm in a GeneChip® Hybridization Oven 640 
(Affymetrix). Arrays were washed and stained using the FS450_0001 protocol at the 
GeneChip® Fluidics Station 450 (Affymetrix) and scanned at the Affymetrix GeneChip® 
Scanner 3000 7G (Affymetrix) and the corresponding software. The resulting image files of 
the arrays were inspected manually for any damage and the CEL intensity files (.cel) were 
used for further data analysis. 
Bioinformatics analysis 
Tiling array output data consist of fluorescence intensities, which refer to the amount of DNA 
sample that is hybridized to a single target within the yeast genome, represented by probes on 
the array. The output of the microarray scanner is a .cel file containing the intensities. An 
additional array specific .bpmap file then maps the intensities of the probes on the array to 
their position in the yeast genome.  
Firstly, the data has to be normalized to be able to compare it to other array experiments and 
to account for saturation effects and sequence specific biases. This was done using R (255) 
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and Bioconductor (256). The R package Starr (257) was used for data import and conversion 
to the basic Bioconductor object class for microarray data, ExpressionSet. Data normalization 
was performed in three steps: (i) Quantile normalization between replicates – biological 
duplicates of each factor/experiment were analyzed, except for Figure 14 (one replicate);  
(ii) for each condition (including the reference measurements) we averaged the signal for each 
probe by calculating the geometric average over replicate intensities; (iii) data from TAP-
tagged factors was normalized using a combined mock IP (ChIP with an untagged strain) plus 
input reference normalization; data from ChIP with specific antibodies was normalized by 
dividing through input reference intensities as no mock IP can be performed with the same 
antibody. Normalized signal was converted to occupancy values between 0-100% by setting 
the genome-wide 99.8% quantile to 100% occupancy and the 10% quantile to 0% occupancy. 
Further details of data normalization are described in (43). 
Secondly, transcript-wise occupancy profiles were generated by calculating the normalized 
occupancy profiles as the median signal of all probes overlapping each nucleotide position 
(6.5 probes on average). Probe intensities were smoothed using sliding window smoothing  
(R package Ringo (258)) or running median smoothing (window half size of 75 bp). 
Thirdly, occupancy profiles were averaged over sets of genes. Therefore, yeast genes were 
filtered first: Of all nuclear protein-coding genes of S. cerevisiae S288C that were classified 
by the Saccharomyces Genome Database as “verified” or “uncharacterized” 
(http://www.yeastgenome.org/, 5769 genes), only 4,366 genes have annotated TSS and pA 
sites (10), which are necessary to align genes. If the TSS was annotated downstream of the 
ATG codon or the pA site upstream of the Stop codon, the genes were excluded. This was 
done also for genes for which the distance between TSS and ATG or pA and Stop was longer 
than 200 bp to exclude wrongly annotated TSS/pA sites. 3448 genes remained. As the yeast 
genome is very compact and the resolution of ChIP-chip experiments limited, profiles can be 
influenced by neighbouring genes. This “spill-over” could be minimized by focusing on genes 
that show a minimum ORF (transcript) distance to neighbouring genes of 250 bp (200 bp), 
leaving 1786 genes for analysis. From these, we analyzed the 50% most highly expressed 
genes ((217), 1140 genes). Genes were divided into four length classes: Xtremely Short (XS, 
256-511 bp, 93 genes), Short (S, 512-937 bp, 266 genes), Medium (M, 938-1537 bp,  
339 genes) and Long (L, 1538-2895 bp, 299 genes). Profiles within these groups were scaled 
to median gene length and the gene-averaged profiles were calculated by taking the median 
over genes at each genomic position.  
Profiles in chapter 3 were cut around the pA site from 400 bp upstream to 400 bp 
downstream. Since CPF acts around the pA site, we were especially interested in whether the 
profiles change around the pA site relative to the region upstream of the pA site. To better 
visualize these relative differences we further normalized the data to have approximately 
equal occupancy levels upstream (around -400 bp) of the pA site for the ‘–‘ and ‘+’ 
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rapamycin treated profiles. Corresponding non-normalized data averaged over the entire gene 
length (250 bp upstream of TSS to 400 bp downstream of pA site) are shown in Figure 16. 
Only genes longer than 800 bp and with at least 400 bp distance to downstream genes were 
included (619 genes) and averaged at each genomic position. 
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